

WEBMD CORP /NEW/  
Form 10-Q  
May 13, 2003

Table of Contents

---

---

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2003

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-24975

**WEBMD CORPORATION**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction of incorporation or organization)*

**94-3236644**

*(I.R.S. Employer Identification Number)*

**669 River Drive, Center 2**

**Elmwood Park, New Jersey 07407-1361**

*(Address of principal executive offices)*

**(201) 703-3400**

*(Registrant's telephone number, including area code)*

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the Exchange Act) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of May 8, 2003, there were 303,120,851 shares of the

registrant's Common Stock outstanding.



**TABLE OF CONTENTS**

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

**PART I**

**ITEM 1. Financial Statements**

**CONSOLIDATED BALANCE SHEETS**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

**ITEM 4. Controls and Procedures**

**PART II OTHER INFORMATION**

**ITEM 2. Changes in Securities and Use of Proceeds**

**ITEM 6. Exhibits and Reports on Form 8-K**

**SIGNATURES**

**CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

**EXHIBIT INDEX**

**EX-99.1 SECTION 906 CERTIFICATION OF THE CEO**

**EX-99.2 SECTION 906 CERTIFICATION OF THE CFO**

---

**Table of Contents**

**WEBMD CORPORATION**  
**QUARTERLY REPORT ON FORM 10-Q**

**For the period ended March 31, 2003**

**TABLE OF CONTENTS**

|  | <b>Page<br/>Number</b> |
|--|------------------------|
| Cautionary Statement Regarding Forward-Looking Statements  | 3                      |
| Part I Financial Information   |                        |
| Item 1. Financial Statements:  |                        |
| Consolidated Balance Sheets as of March 31, 2003 (unaudited) and December 31, 2002                 | 4                      |
| Unaudited Consolidated Statements of Operations for the three months ended March 31, 2003 and 2002 | 5                      |
| Unaudited Consolidated Statements of Cash Flows for the three months ended March 31, 2003 and 2002 | 6                      |
| Notes to Consolidated Financial Statements   | 7                      |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations      | 17                     |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk                                 | 39                     |
| Item 4. Controls and Procedures  | 39                     |
| Part II Other Information  |                        |
| Item 2. Changes in Securities and Use of Proceeds  | 40                     |
| Item 6. Exhibits and Reports on Form 8-K   | 40                     |
| Signatures   | 41                     |
| Exhibit Index  | E-1                    |

WebMD®, WebMD Health®, The Medical Manager®, ULTIA™, Intergy™, Envoy®, ExpressBill®, Medscape®, WellMed® and POREX® are trademarks of WebMD Corporation or its subsidiaries.

**Table of Contents**

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, forward-looking statements. These forward-looking statements are not based on historical facts, but rather reflect management's current expectations concerning future results and events. These forward-looking statements generally can be identified by use of expressions such as believe, expect, anticipate, intend, plan, foresee, likely, will or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. In addition to the risk factors described in Management's Discussion and Analysis of Financial Condition and Results of Operations Factors That May Affect Our Future Financial Condition or Results of Operations beginning on page 26, the following important risks and uncertainties could affect future results, causing these results to differ materially from those expressed in our forward-looking statements:

the failure to achieve sufficient levels of customer utilization and market acceptance of new services or newly integrated services,

the inability to successfully deploy new applications or newly integrated applications,

difficulties in forming and maintaining mutually beneficial relationships with customers and strategic partners,

the inability to attract and retain qualified personnel, and

general economic, business or regulatory conditions affecting the healthcare, information technology, Internet and plastic industries being less favorable than expected.

These factors and the risk factors described in Management's Discussion and Analysis of Financial Condition and Results of Operations Factors That May Affect Our Future Financial Condition or Results of Operations beginning on page 26 are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could have material adverse effects on our future results. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this Quarterly Report. We expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

**Table of Contents****PART I****FINANCIAL INFORMATION****ITEM 1. Financial Statements****WEBMD CORPORATION****CONSOLIDATED BALANCE SHEETS**  
(In thousands, except share and per share data)

|   | March 31,<br>2003 | December 31,<br>2002 |
|---|-------------------|----------------------|
|   | _____             | _____                |
|   | (Unaudited)       |                      |
| <b>ASSETS</b>   |                   |                      |
| Current assets:   |                   |                      |
| Cash and cash equivalents   | \$ 252,652        | \$ 179,541           |
| Short-term investments  | 214,276           | 10,888               |
| Accounts receivable, net  | 176,571           | 170,467              |
| Inventory   | 18,489            | 18,804               |
| Current portion of prepaid content and distribution services  | 25,660            | 25,406               |
| Other current assets  | 18,447            | 26,197               |
|   | _____             | _____                |
| Total current assets  | 706,095           | 431,303              |
| Marketable debt securities  | 218,602           | 449,289              |
| Marketable equity securities  | 7,407             | 7,427                |
| Property and equipment, net   | 91,714            | 94,737               |
| Prepaid content and distribution services   | 42,324            | 48,532               |
| Goodwill  | 629,217           | 629,055              |
| Intangible assets, net  | 58,989            | 79,536               |
| Other assets  | 26,240            | 26,369               |
|   | _____             | _____                |
|   | \$ 1,780,588      | \$ 1,766,248         |
|   | _____             | _____                |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b>  |                   |                      |
| Current liabilities:  |                   |                      |
| Accounts payable  | \$ 11,711         | \$ 11,494            |
| Accrued expenses  | 207,992           | 212,600              |
| Deferred revenue  | 85,365            | 81,179               |
| Current portion of long-term debt   | 6,546             | 6,546                |
|   | _____             | _____                |
| Total current liabilities   | 311,614           | 311,819              |
| Convertible subordinated notes  | 300,000           | 300,000              |
| Other long-term liabilities   | 605               | 628                  |
| Commitments and contingencies   |                   |                      |
| Stockholders equity:  |                   |                      |
| Common stock, \$0.0001 par value; 600,000,000 shares authorized; 378,482,167 shares issued at March 31, 2003; | 38                | 37                   |

Edgar Filing: WEBMD CORP /NEW/ - Form 10-Q

|   |                             |                             |
|---|-----------------------------|-----------------------------|
| 374,661,064 shares issued at December 31, 2002.   |                             |                             |
| Additional paid-in capital  | 11,699,274                  | 11,682,443                  |
| Deferred stock compensation   | (13,836)                    | (17,805)                    |
| Treasury stock, at cost; 74,265,669 shares at March 31, 2003; 74,254,669 shares at December 31, 2002. | (327,635)                   | (327,542)                   |
| Accumulated deficit   | (10,202,406)                | (10,195,048)                |
| Accumulated other comprehensive income  | 12,934                      | 11,716                      |
|   | <u>                    </u> | <u>                    </u> |
| Total stockholders equity   | 1,168,369                   | 1,153,801                   |
|   | <u>                    </u> | <u>                    </u> |
|   | \$ 1,780,588                | \$ 1,766,248                |
|   | <u>                    </u> | <u>                    </u> |

See accompanying notes.



Table of Contents

## WEBMD CORPORATION

**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(In thousands, except per share data, unaudited)

|  | Three Months Ended<br>March 31, |             |
|--|---------------------------------|-------------|
|  | 2003                            | 2002        |
| Revenue  | \$ 234,743                      | \$ 225,873  |
| Costs and expenses:  |                                 |             |
| Cost of operations   | 134,380                         | 138,531     |
| Development and engineering  | 11,012                          | 10,868      |
| Sales, marketing, general and administrative   | 70,070                          | 79,366      |
| Depreciation and amortization  | 27,976                          | 32,759      |
| Restructuring and integration benefit  |                                 | 3,750       |
| Gain on investments  | 183                             |             |
| Interest income  | 5,055                           | 3,140       |
| Interest expense   | 2,921                           | 141         |
|  | (6,378)                         | (28,902)    |
| Loss before income tax provision   |                                 |             |
| Income tax provision   | 980                             | 700         |
|  | \$ (7,358)                      | \$ (29,602) |
| Net loss   |                                 |             |
|  | \$ (0.02)                       | \$ (0.09)   |
| Basic and diluted net loss per common share  |                                 |             |
|  | 302,892                         | 311,668     |
| Weighted-average shares outstanding used in computing basic<br>and diluted net loss per common share |                                 |             |

See accompanying notes.

Table of Contents

## WEBMD CORPORATION

**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands, unaudited)

|   | Three Months Ended<br>March 31, |             |
|---|---------------------------------|-------------|
|   | 2003                            | 2002        |
| <b>Cash flows from operating activities:</b>                                    |                                 |             |
| Net loss  | \$ (7,358)                      | \$ (29,602) |
| Adjustments to reconcile net loss to net cash provided by operating activities: |                                 |             |
| Depreciation and amortization   | 27,976                          | 32,759      |
| Amortization of debt issuance costs   | 375                             |             |
| Non-cash content and distribution services                                      | 6,146                           | 7,260       |
| Non-cash stock-based compensation   | 3,757                           | 7,576       |
| Gain on investments   | (183)                           |             |
| Changes in operating assets and liabilities:                                    |                                 |             |
| Accounts receivable   | (6,074)                         | (1,692)     |
| Inventory   | 315                             | (1,894)     |
| Prepaid content and distribution services                                       | (191)                           | (1,649)     |
| Accounts payable  | 190                             | (3,389)     |
| Accrued expenses  | (4,610)                         | 10,049      |
| Deferred revenue  | 4,112                           | 8,393       |
| Other, net  | 9,495                           | 807         |
| Net cash provided by operating activities                                       | 33,950                          | 28,618      |
| <b>Cash flows from investing activities:</b>                                    |                                 |             |
| Proceeds from maturities of available-for-sale securities                       | 801                             | 79,248      |
| Proceeds from maturities and redemptions of held-to-maturity securities         | 101,919                         | 1,055       |
| Purchases of available-for-sale securities                                      | (1,164)                         |             |
| Purchases of held-to-maturity securities  | (75,119)                        | (156,714)   |
| Purchases of property and equipment   | (4,022)                         | (5,753)     |
| Cash paid in business combinations, net of cash acquired                        | (344)                           | (1,142)     |
| Net cash provided by (used in) investing activities                             | 22,071                          | (83,306)    |
| <b>Cash flows from financing activities:</b>                                    |                                 |             |
| Proceeds from issuance of common stock  | 17,025                          | 5,351       |
| Payments of notes payable and other   | (19)                            | (645)       |
| Redemption of Series B Preferred Stock  |                                 | (10,000)    |
| Purchases of treasury stock   | (93)                            |             |
| Net cash provided by (used in) financing activities                             | 16,913                          | (5,294)     |
| Effect of exchange rates on cash  | 177                             | (121)       |
| Net increase (decrease) in cash and cash equivalents                            | 73,111                          | (60,103)    |
| Cash and cash equivalents at beginning of period                                | 179,541                         | 286,273     |
| Cash and cash equivalents at end of period                                      | \$ 252,652                      | \$ 226,170  |

See accompanying notes.

**Table of Contents**

**WEBMD CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(In thousands, except share and per share data, unaudited)**

**1. Summary of Significant Accounting Policies**

**Basis of Presentation**

The unaudited consolidated financial statements of WebMD Corporation (the Company) have been prepared by management and reflect all adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three months ended March 31, 2003 are not necessarily indicative of the results to be expected for any subsequent period or for the entire year ending December 31, 2003. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted under the Securities and Exchange Commission's rules and regulations.

Porex Corporation and the Company's other Plastic Technologies subsidiaries (collectively referred to as Porex) had previously been reported as an asset held for sale during the period from September 12, 2000 to September 12, 2001, and as a discontinued operation from September 13, 2001 to September 30, 2002. During February 2003, the Company terminated its divestiture plan for Porex. Accordingly, the assets and operations of Porex have been reclassified within continuing operations since September 12, 2000, its date of acquisition. The operations of Porex have been included in a separate operating segment, Plastic Technologies.

The unaudited consolidated financial statements and notes included herein should be read in conjunction with the Company's audited consolidated financial statements and notes for the year ended December 31, 2002, which were included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

**Accounting Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from these estimates. Significant estimates and assumptions by management affect: the Company's allowance for doubtful accounts, the carrying value of inventory, the carrying value of prepaid content and distribution services, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill), the carrying value, capitalization and amortization of software development costs, the carrying value of short-term and long-term investments, the provision for taxes and related deferred tax accounts, certain accrued expenses, revenue recognition, restructuring costs and the value attributed to warrants issued for services.

**Inventory**

Inventory is stated at the lower of cost or market value using the first-in, first-out basis. Cost includes raw materials, direct labor, and manufacturing overhead. Market value is based on current replacement

**Table of Contents****WEBMD CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

cost for raw materials and supplies and on net realizable value for work-in-process and finished goods. Inventory consisted of the following as of March 31, 2003 and December 31, 2002:

|                            | <b>March 31,<br/>2003</b> | <b>December 31,<br/>2002</b> |
|----------------------------|---------------------------|------------------------------|
| Raw materials and supplies | \$ 5,526                  | \$ 5,869                     |
| Work-in-process            | 1,594                     | 1,481                        |
| Finished goods and other   | 11,369                    | 11,454                       |
|                            | <u>\$ 18,489</u>          | <u>\$ 18,804</u>             |

**Accounting for Stock-Based Compensation**

The Company accounts for its stock-based employee compensation plans using the intrinsic value method under the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees ( APB No. 25 ), and related interpretations. No stock-based employee compensation cost is reflected in net loss with respect to options granted with an exercise price equal to the market value of the underlying common stock on the date of grant. Stock-based awards to non-employees are accounted for based on provisions of SFAS No. 123, Accounting for Stock-Based Compensation ( SFAS No. 123 ) and EITF 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services. In accordance with SFAS No. 148 Accounting for Stock-Based Compensation Transition and Disclosure An Amendment of FASB Statement No. 123, the following table illustrates the effect on net loss and net loss per share if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation:

|  | <b>Three Months Ended<br/>March 31,</b> |                    |
|--|---|--------------------|
|  | <b>2003</b>                             | <b>2002</b>        |
| Net loss as reported   | \$ (7,358)                              | \$ (29,602)        |
| Deduct: Stock-based employee compensation expense included in reported net loss                              | 3,757                                   | 7,576              |
| Add: Total stock-based employee compensation expense determined under fair value based method for all awards | (17,958)                                | (32,782)           |
| Pro forma net loss   | <u>\$ (21,559)</u>                      | <u>\$ (54,808)</u> |
| Net loss per common share:   |   |                    |
| Basic and diluted as reported  | <u>\$ (0.02)</u>                        | <u>\$ (0.09)</u>   |
| Basic and diluted pro forma  | <u>\$ (0.07)</u>                        | <u>\$ (0.18)</u>   |

The pro forma results above are not intended to be indicative of or a projection of future results. Pro forma information regarding net loss has been determined as if employee stock options granted subsequent to December 31, 1994 were accounted for under the fair value method of SFAS No. 123. The fair value for 2003 options was estimated at the date of grant using the Black-Scholes option pricing model employing weighted average assumptions consistent with the 2002 assumptions, which were included in Note 15 to the Consolidated Financial Statements contained in the Company's 2002 Annual Report on Form 10-K filed with the Securities and Exchange Commission.

## Edgar Filing: WEBMD CORP /NEW/ - Form 10-Q

The Company has elected to follow APB No. 25 and related interpretations in accounting for employee stock options because the alternative fair value accounting method provided for under SFAS No. 123 requires the use of option valuation models that were not developed for use in valuing employee stock options. The Black-Scholes option valuation model was developed for use in estimating the fair value

**Table of Contents**

**WEBMD CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimates, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of the Company's employee stock options.

**Reclassifications**

Certain reclassifications have been made to the prior period financial statements to conform with the current period presentation.

**2. Business Combinations**

**2003 Acquisitions**

During the three months ended March 31, 2003, the Company acquired one physician services company for a cost of \$350, which was paid in cash. This acquisition was accounted for using the purchase method of accounting with the purchase price being allocated to assets acquired and liabilities assumed based on their fair values. In connection with the preliminary allocation of the purchase price, goodwill of \$197 and intangible assets subject to amortization of \$192 were recorded. The Company expects that substantially all of the goodwill recorded will be deductible for tax purposes. The intangible assets are comprised of \$96 related to a non-compete agreement with an estimated useful life of three years and \$96 related to customer relationships with an estimated useful life of nine years. The results of operations of this company have been included in the financial statements of the Company from the acquisition closing date and are included in the Physician Services segment.

**2002 Acquisitions**

On October 31, 2002, the Company acquired WellMed, Inc. ( WellMed ), which develops and markets healthcare information technology applications, including online healthcare decision support and health management tools for use by consumers. The total purchase consideration for WellMed was approximately \$19,031, comprised of \$18,781 in cash and estimated acquisition costs of \$250. The acquisition was accounted for using the purchase method of accounting and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and the liabilities assumed on the basis of their respective fair values. In connection with the preliminary allocation of the purchase price, goodwill of \$17,973 and an intangible asset subject to amortization of \$2,700 were recorded. The Company expects that substantially all of the goodwill recorded will be deductible for tax purposes. The intangible asset represents the fair value of acquired unpatented technology and has a useful life of three years. The results of operations of WellMed have been included in the financial statements of the Company from October 31, 2002, the closing date of the acquisition. WellMed's results of operations are included in the Portal Services segment.

In 2002, the Company acquired 21 physician services companies for a total cost of \$14,400, which was paid in cash. These acquisitions were accounted for using the purchase method of accounting with the purchase price being allocated to assets acquired and liabilities assumed based on their fair values. In connection with the preliminary allocation of the purchase price, goodwill of \$11,784 and intangible assets subject to amortization of \$4,049 were recorded. The Company expects that substantially all of the goodwill recorded will be deductible for tax purposes. The intangible assets are comprised of \$1,281 related to non-compete agreements with estimated useful lives of one to five years and \$2,768 related to customer relationships with estimated useful lives of nine years. The results of operations of these companies have

**Table of Contents****WEBMD CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

been included in the financial statements of the Company from the respective acquisition closing dates and are included in the Physician Services segment.

The pro forma impact of the 2003 Acquisitions and the 2002 Acquisitions was not significant in any of the periods presented.

**3. Restructuring and Integration**

After the mergers with Medical Manager Corporation, CareInsite, Inc. and OnHealth Network Company in September 2000, the Company's Board of Directors approved a restructuring and integration plan, with the objective of eliminating duplication and redundancies that resulted from the acquisitions made by the Company since November 1999 and consolidating the Company's operational infrastructure into a common platform to more efficiently serve its customers.

Additionally, as part of the Company's restructuring and integration efforts, the Company also undertook a review of its existing strategic relationships in light of several criteria, including strategic relevance to both the Company and the Company's partners, potential conflicts with other agreements as a result of the numerous acquisitions made by the Company, profitability and impact on future revenue streams. These reviews resulted in significant revisions to some of the Company's strategic relationships. The Company's restructuring and integration efforts continued in 2001, and a plan to include the impact of eliminating functions resulting from the Company's acquisition of Medscape in December 2001 was initiated. Additionally, the Plastic Technologies segment consolidated a manufacturing facility in 2002 as part of a separate restructuring plan.

The Company has substantially completed its restructuring and integration efforts. The balance of the restructuring and integration accrual as of March 31, 2003 is primarily related to remaining lease payments of previously vacated facilities. The following table presents cash activity in the restructuring and integration related accrual:

|                              | <u>Severance</u>  | <u>Facilities</u> | <u>Total</u>      |
|------------------------------|-------------------|-------------------|-------------------|
| Balance at December 31, 2002 | \$ 244            | \$ 33,613         | \$ 33,857         |
| Accruals                     |                   |                   |                   |
| Cash payments                | (50)              | (1,915)           | (1,965)           |
|                              | <u>          </u> | <u>          </u> | <u>          </u> |
| Balance at March 31, 2003.   | \$ 194            | \$ 31,698         | \$ 31,892         |
|                              | <u>          </u> | <u>          </u> | <u>          </u> |

**4. Stockholders' Equity***Repurchase Program*

On March 29, 2001, the Company announced a stock repurchase program (the "Program"). Under the Program, the Company was originally authorized to use up to \$50,000 to purchase shares of its common stock from time to time beginning on April 2, 2001, subject to market conditions. On November 2, 2001, the maximum aggregate amount of purchases under the Program was increased to \$100,000 and on November 7, 2002 it was increased to \$150,000. As of March 31, 2003, the Company had repurchased a total of 20,002,160 shares at a cost of approximately \$86,135 under the Program, of which 11,000 shares were repurchased during the three months ended March 31, 2003 for an aggregate purchase price of \$93. The Company did not repurchase any of its common stock during the three months ended March 31, 2002. These repurchased shares are reflected as treasury stock in the accompanying consolidated balance sheets. As of March 31, 2003, the Company had \$63,865 available to repurchase shares of its common stock under the Program.



**Table of Contents**

**WEBMD CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Series B Convertible Redeemable Preferred Stock*

In September 2000, the Board of Directors authorized 200 shares of Series B Convertible Redeemable Preferred Stock ( Series B Preferred ). In connection with the acquisition of CareInsite, the Company issued 100 shares of Series B Preferred in exchange for all the outstanding shares of CareInsite's preferred stock. The Series B Preferred was convertible in March 2002 into an aggregate of 263,957 shares of common stock (conversion price of \$37.885) plus a warrant to acquire an equal number of shares at \$37.885 per share. Additionally, the Series B Preferred was redeemable for an aggregate of \$10,000 at the option of the Company or the holder in March 2002 or at the option of the holder following the notice of a change of control of the Company. In March 2002, the Company redeemed the outstanding Series B Preferred for \$10,000 in accordance with its terms.

**5. Convertible Subordinated Notes and Long-Term Debt**

On April 1, 2002, the Company issued \$300,000 aggregate principal amount of 3 1/4% Convertible Subordinated Notes due 2007 (the Notes ) in a private offering. Interest on the Notes will accrue at the rate of 3 1/4% per annum and is payable semi-annually on April 1 and October 1 of each year. Unless previously redeemed or converted, the Notes will mature on April 1, 2007. The Notes are convertible into an aggregate of approximately 32,386,916 shares of the Company's common stock, subject to adjustment in certain circumstances. The Notes are redeemable at the Company's option, at any time on or after April 5, 2005. The redemption price, as a percentage of principal amount, is 101.3% beginning April 5, 2005 and 100.65% beginning April 1, 2006. The Company incurred issuance costs related to the Notes of \$8,000, which are included in other assets in the accompanying consolidated balance sheets. The issuance costs are being amortized using the effective interest method over the term of the Notes. The amortization of the issuance costs is included in interest expense.

As of March 31, 2003, the Company's long-term and short-term debt totaled \$6,661. The largest component within this balance is a \$6,531 note payable bearing interest at 6.23% per annum, which was paid in full on April 1, 2003. Remaining amounts relate to capital leases and other notes payable which are not material, individually or in the aggregate, to the Company's consolidated financial position.

**6. Segment Information**

Segment information has been prepared in accordance with the Statement of Financial Accounting Standards No. 131, Disclosures about Segments of an Enterprise and Related Information ( SFAS No. 131 ). The accounting policies of the segments are the same as the accounting policies for the consolidated Company. Inter-segment revenues represent sales of Transaction Services products into the Physician Services customer base and are reflected at rates comparable to those charged to third parties for comparable services. The performance of the Company's business is monitored based on income or loss before restructuring, taxes, non-cash and other items. Non-cash and other items include depreciation, amortization, gain on investments, non-cash expenses related to content, advertising and distribution services acquired in exchange for the Company's equity securities in acquisitions and strategic alliances, and stock compensation expense primarily related to stock options issued and assumed in connection with acquisitions.

The Company has aligned its business into four operating segments as follows:

*Transaction Services or WebMD Envoy* transmits transactions between healthcare payers and physicians, pharmacies, dentists, hospitals, laboratory companies and other healthcare providers using dial-up, Internet, and dedicated communication methods. This group provides connectivity and transaction services through an integrated electronic transaction processing system. These services assist the group's

**Table of Contents****WEBMD CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

customers in automating key administrative and clinical functions. In addition, this group provides automated patient billing services to providers, including statement printing and mailing services.

*Physician Services or WebMD Medical Manager* develops and markets integrated physician practice management systems, including administrative, financial and clinical applications and services, under The Medical Manager, Intergy, ULTIA and Medical Manager Network Services brands. These systems and services allow physician offices to automate their scheduling, billing and other administrative tasks, to maintain electronic medical records and to automate documentation of patient encounters.

*Portal Services or WebMD Health* provides online healthcare information and related resources and services for consumers and healthcare professionals, both directly and through its relationships with leading general consumer Internet portals. The group also provides online content for use by media and healthcare partners on their Web sites. The group develops and sells online and offline programs for advertisers and sponsors, particularly those who are interested in influencing healthcare decisions.

*Plastic Technologies or Porex* develops, manufactures and distributes proprietary porous and solid plastic products and components used in healthcare, industrial and consumer applications, as well as in finished products used in medical device, research, clinical laboratory and surgical markets.

Summarized financial information for each of the Company's operating segments and a reconciliation to net loss is presented below:

|  | <b>Three Months Ended<br/>March 31,</b> |                   |
|--|---|-------------------|
|  | <b>2003</b>                             | <b>2002</b>       |
| <b>Revenues</b>  |   |                   |
| Transaction services   | \$ 115,493                              | \$ 117,927        |
| Physician services   | 72,011                                  | 66,089            |
| Portal services  | 22,180                                  | 17,134            |
| Plastic technologies   | 30,538                                  | 29,541            |
| Inter-segment eliminations   | (5,479)                                 | (4,818)           |
|  | <u>\$ 234,743</u>                       | <u>\$ 225,873</u> |
| <b>Income (loss) before restructuring, taxes, non-cash and other items</b> |   |                   |
| Transaction services   | \$ 24,051                               | \$ 17,538         |
| Physician services   | 6,297                                   | 6,252             |
| Portal services  | 4,018                                   | (4,837)           |
| Plastic technologies   | 7,280                                   | 7,598             |
| Corporate  | (12,462)                                | (14,607)          |
| Interest income  | 5,055                                   | 3,140             |
| Interest expense   | (2,921)                                 | (141)             |
|  | <u>\$ 31,318</u>                        | <u>\$ 14,943</u>  |
| <b>Restructuring, taxes, non-cash and other items</b>                      |   |                   |
| Depreciation and amortization  | \$ (27,976)                             | \$ (32,759)       |
| Non-cash content and distribution services and stock compensation          | (9,903)                                 | (14,836)          |
| Restructuring and integration benefit                                      |   | 3,750             |
| Gain on investments  | 183                                     |                   |

Edgar Filing: WEBMD CORP /NEW/ - Form 10-Q

|                      |            |             |
|----------------------|------------|-------------|
| Income tax provision | (980)      | (700)       |
| Net loss             | \$ (7,358) | \$ (29,602) |

**Table of Contents****WEBMD CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****7. Fair Value of Financial Instruments**

The following disclosure of the estimated fair value of financial instruments is made in accordance with the requirements of SFAS No. 107, Disclosures about Fair Value of Financial Instruments. The estimated fair values have been determined using available market information. However, considerable judgment is required in interpreting market data to develop estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

|                                 | March 31, 2003 |            | December 31, 2002 |            |
|---------------------------------|----------------|------------|-------------------|------------|
|                                 | Cost Basis     | Fair Value | Cost Basis        | Fair Value |
| <b>Assets:</b>                  |                |            |                   |            |
| Cash and cash equivalents       | \$ 252,652     | \$ 252,652 | \$ 179,541        | \$ 179,541 |
| Short-term investments          | 209,176        | 214,276    | 10,865            | 10,897     |
| Marketable securities long-term | 221,772        | 233,502    | 448,286           | 464,638    |
| <b>Liability:</b>               |                |            |                   |            |
| Convertible subordinated notes  | \$ 300,000     | \$ 369,819 | \$ 300,000        | \$ 348,000 |

In accordance with the requirements of SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, below is a summary of the fair value and gains relating to the Company's investments in debt and equity securities:

|  | March 31, 2003         |                        |            | December 31, 2002      |                        |            |
|--|------------------------|------------------------|------------|------------------------|------------------------|------------|
|  | Cost or Amortized Cost | Gross Unrealized Gains | Fair Value | Cost or Amortized Cost | Gross Unrealized Gains | Fair Value |
| <b>Short-Term</b>                                      |                        |                        |            |                        |                        |            |
| Held to maturity:                                      |                        |                        |            |                        |                        |            |
| Certificate of deposits and marketable debt securities | \$ 1,000               | \$                     | \$ 1,000   | \$ 2,919               | \$ 9                   | \$ 2,928   |
| Available for sale:                                    |                        |                        |            |                        |                        |            |
| Certificate of deposits and marketable debt securities | 208,176                | 5,100                  | 213,276    | 7,946                  | 23                     | 7,969      |
| Total  | \$ 209,176             | \$ 5,100               | \$ 214,276 | \$ 10,865              | \$ 32                  | \$ 10,897  |
| <b>Long-Term</b>                                       |                        |                        |            |                        |                        |            |
| Held to maturity:                                      |                        |                        |            |                        |                        |            |
| Marketable debt securities                             | \$ 218,602             | \$ 7,493               | \$ 226,095 | \$ 243,475             | \$ 7,922               | \$ 251,397 |
| Available for sale:                                    |                        |                        |            |                        |                        |            |
| Marketable debt securities                             |                        |                        |            | 201,641                | 4,173                  | 205,814    |
| Equity securities                                      | 3,170                  | 4,237                  | 7,407      | 3,170                  | 4,257                  | 7,427      |
| Total  | \$ 221,772             | \$ 11,730              | \$ 233,502 | \$ 448,286             | \$ 16,352              | \$ 464,638 |



As of March 31, 2003, the Company's short-term investments consisted of certificates of deposit, U.S. Treasury Notes, municipal bonds and asset-backed securities, marketable debt securities consisted of Federal Agency Notes and U.S. Treasury Notes and marketable equity securities consisted of an equity investment in a publicly traded company. As of December 31, 2002, the Company's short-term

**Table of Contents****WEBMD CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

investments consisted of certificates of deposit, municipal bonds and asset-backed securities, marketable debt securities consisted of Federal Agency Notes and U.S. Treasury Notes and marketable equity securities consisted of an equity investment in a publicly traded company.

The amortized cost and estimated fair value by maturity of securities are shown in the following table. Securities are classified according to their contractual maturities without consideration of principal amortization, potential prepayments or call options. Accordingly, actual maturities may differ from contractual maturities.

|                                       | <u>Cost or<br/>Amortized Cost</u> | <u>Fair Value</u> |
|---------------------------------------|-----------------------------------|-------------------|
| <b>Held to maturity:</b>              |                                   |                   |
| Due in one year or less               | \$ 1,000                          | \$ 1,000          |
| Due after one year through five years | 218,602                           | 226,095           |
|                                       | <u>          </u>                 | <u>          </u> |
| Total                                 | \$219,602                         | \$227,095         |
|                                       | <u>          </u>                 | <u>          </u> |
| <b>Available for sale:</b>            |                                   |                   |
| Due in one year or less               | \$208,176                         | \$213,276         |
|                                       | <u>          </u>                 | <u>          </u> |

**8. Net Loss Per Common Share**

Basic net loss per common share and diluted net loss per common share are presented in conformity with SFAS No. 128, Earnings Per Share, ( SFAS No. 128 ) for all periods presented. In accordance with SFAS No. 128, basic net loss per common share has been computed using the weighted-average number of shares of common stock outstanding during the period.

The Company has excluded all convertible subordinated notes and restricted stock as well as all outstanding warrants and all outstanding stock options from the calculation of diluted loss per common share because all such securities are anti-dilutive for the periods presented. The total number of shares excluded from the calculations of diluted loss per share were 163,670,867 and 155,770,641 for the three months ended March 31, 2003 and 2002, respectively.

**9. Comprehensive Loss**

Comprehensive loss is comprised of net loss and other comprehensive income. Other comprehensive income includes certain changes in equity that are excluded from net loss, such as changes in unrealized holding gains on available-for-sale marketable securities and foreign currency translation adjustments. During the three months ended March 31, 2003 and 2002, unrealized holding gains increased by \$884 and \$985 and foreign currency translation gains (losses) were \$334 and (\$211), respectively. Comprehensive loss for the three months ended March 31, 2003 and 2002 was \$6,140 and \$28,828, respectively.

**10. Goodwill and Other Intangible Assets**

The changes in the carrying amount of goodwill for the three months ended March 31, 2003 are as follows:

|                                     | <u>Transaction<br/>Services</u> | <u>Physician<br/>Services</u> | <u>Portal<br/>Services</u> | <u>Plastic<br/>Technologies</u> | <u>Total</u> |
|-------------------------------------|---------------------------------|-------------------------------|----------------------------|---------------------------------|--------------|
| Balance as of January 1, 2003.      | \$341,967                       | \$182,085                     | \$23,705                   | \$81,298                        | \$629,055    |
| Goodwill recorded during the period |                                 | 197                           |                            |                                 | 197          |

Edgar Filing: WEBMD CORP /NEW/ - Form 10-Q

|                               |            |            |           |           |            |
|-------------------------------|------------|------------|-----------|-----------|------------|
| Effects of exchange rates     |            |            |           | (35)      | (35)       |
| Balance as of March 31, 2003. | \$ 341,967 | \$ 182,282 | \$ 23,705 | \$ 81,263 | \$ 629,217 |

**Table of Contents****WEBMD CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Intangible assets subject to amortization consist of the following:

|                        | March 31, 2003        |                          |                  | December 31, 2002     |                          |                  |
|------------------------|-----------------------|--------------------------|------------------|-----------------------|--------------------------|------------------|
|                        | Gross Carrying Amount | Accumulated Amortization | Net              | Gross Carrying Amount | Accumulated Amortization | Net              |
| Customer lists         | \$ 209,482            | \$ (196,397)             | \$ 13,085        | \$ 209,386            | \$ (179,127)             | \$ 30,259        |
| Trade names            | 29,629                | (16,900)                 | 12,729           | 29,629                | (14,318)                 | 15,311           |
| Non-compete agreements | 2,364                 | (431)                    | 1,933            | 2,268                 | (295)                    | 1,973            |
| Technology and patents | 176,660               | (145,418)                | 31,242           | 176,660               | (144,667)                | 31,993           |
| <b>Total</b>           | <b>\$ 418,135</b>     | <b>\$ (359,146)</b>      | <b>\$ 58,989</b> | <b>\$ 417,943</b>     | <b>\$ (338,407)</b>      | <b>\$ 79,536</b> |

Amortization expense was \$20,739 and \$26,024 for the three months ended March 31, 2003 and 2002, respectively. Aggregate amortization expense for intangible assets is estimated to be:

| Year ending December 31, |           |
|--------------------------|-----------|
| 2003                     | \$ 33,205 |
| 2004                     | 6,402     |
| 2005                     | 5,050     |
| 2006                     | 2,289     |
| 2007                     | 1,713     |
| Thereafter               | 31,069    |

**11. Recent Accounting Pronouncements**

In December 2002, the FASB issued SFAS No. 148, *Accounting for Stock-Based Compensation Transition and Disclosure*. An Amendment of FASB Statement No. 123 (SFAS No. 148). The statement provides alternative methods of transition for a voluntary change to the fair value method of accounting for stock-based employee compensation. In addition, the statement requires the Company to disclose, in both annual and interim financial statements, the method of accounting for stock-based compensation and the effect of the method used on reported results. The statement is effective for annual periods ending after December 15, 2002 and interim periods beginning after December 15, 2002. The Company applies the intrinsic value method of accounting for stock-based employee compensation. The adoption of SFAS No. 148 did not have a material impact on the Company's consolidated financial position or results of operations.

In November 2002, the FASB issued Interpretation No. 45, *Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others* (FIN 45). The interpretation elaborates on the disclosures to be made in the Company's interim and annual financial statements about obligations under certain guarantees. It also requires the Company to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The disclosure requirements are effective for financial statements of interim and annual periods ending after December 15, 2002. The initial measurement and recognition provisions are required to be applied on a prospective basis to guarantees issued or modified after December 31, 2002. The adoption of FIN 45 did not have any impact on the Company's consolidated financial position or results of operations.

In June 2002, the FASB issued SFAS No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*. SFAS No. 146 requires recording costs associated with exit or disposal activities at their fair values when a liability has been incurred. Under previous guidance, certain exit costs were accrued upon management's commitment to an exit plan, which is generally before an actual liability has been incurred. SFAS No. 146 is effective for exit or disposal activities initiated after December 31, 2002. SFAS No. 146 will have an impact on the timing of the recording of any future restructuring charges.





**Table of Contents**

**WEBMD CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

In August 2001, the FASB issued SFAS No. 144, Accounting For Impairment of Long-Lived Assets ( SFAS No. 144 ). We adopted this pronouncement beginning January 1, 2002. SFAS No. 144 prescribes the accounting for long-lived assets (excluding goodwill) to be disposed of by sale. SFAS No. 144 retains the requirement of SFAS No. 121 to measure long-lived assets classified as held for sale at the lower of their carrying value or fair market value less the cost to sell. Therefore, discontinued operations are no longer measured on a net realizable basis, and future operating results are no longer recognized before they occur. The adoption of SFAS No. 144 on January 1, 2002 did not have any impact on the Company's consolidated financial condition or results of operations.

In June 2001, the FASB issued SFAS No. 143, Accounting for Asset Retirement Obligations, which establishes accounting standards for recognition and measurement of a liability for the costs of asset retirement obligations. Under SFAS No. 143, the future costs of retiring a tangible long-lived asset will be recorded as a liability at its present value when the retirement obligation arises, and will be amortized to expense over the life of the asset. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. The adoption of SFAS No. 143 did not have any impact on our consolidated financial position or results of operations.

**12. Commitments and Contingencies**

In the normal course of business, the Company and its subsidiaries are involved in various claims and legal proceedings. While the ultimate resolution of these matters, including those discussed in the Company's 2002 Annual Report on Form 10-K under the heading Legal Proceedings, has yet to be determined, the Company does not believe that their outcome will have a material adverse effect on the Company's financial position or results of operations.

**Table of Contents**

**ITEM 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations***

The following discussion reflects our Plastic Technologies business, Porex, as a continuing operation since the date of its acquisition on September 12, 2000. Previously, Porex had been accounted for as an asset held for sale during the period from September 12, 2000 to September 12, 2001, and as discontinued operations subsequent to September 12, 2001. During February 2003, we terminated our formal divestiture efforts relating to Porex.

*This Item 2 contains forward-looking statements with respect to possible events, outcomes or results that are, and are expected to continue to be, subject to risks, uncertainties and contingencies, including those identified in this Item. See Cautionary Statement Regarding Forward-Looking Statements on page 3.*

All amounts are reflected in thousands, except share and per share data, unless otherwise noted.

**Critical Accounting Policies and Estimates**

Our discussion and analysis of WebMD's financial condition and results of operations are based upon our Consolidated Financial Statements and Notes to Consolidated Financial Statements, which were prepared in conformity with accounting principles generally accepted in the United States. The preparation of the consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. We base our estimates on historical experience, current business factors, and various other assumptions that we believe are necessary to form a basis for making judgments about the carrying values of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates.

We evaluate our estimates on an ongoing basis, including those related to revenue recognition, short-term and long-term investments, deferred tax assets, income taxes, collectibility of customer receivables, prepaid content and distribution services, long-lived assets including goodwill and other intangible assets, software development costs, inventory valuation, certain accrued expenses, accruals related to our restructuring program, contingencies and litigation.

We believe the following reflect our critical accounting policies and our more significant judgments and estimates used in the preparation of our consolidated financial statements:

*Revenue.* Our revenue recognition policies for each reportable segment are as follows:

*Transaction Services or WebMD Envoy.* Healthcare payers and providers pay us fees for our services, generally on a per transaction basis or monthly basis. We recognize revenue as we perform the service. Healthcare payers and providers also pay us one-time implementation and annual maintenance fees. We recognize revenue from these fees ratably over the term of the respective agreements.

*Physician Services or WebMD Medical Manager.* Healthcare providers pay us one-time fees for the purchase of our practice management systems. We recognize revenue from these one-time fees when we enter into noncancelable agreements with our customers, the products have been delivered and there are no uncertainties regarding product acceptance and delivery and no significant future performance obligations. Amounts received in advance of meeting these criteria are deferred until we meet these criteria. Revenue from multiple-element software arrangements is recognized using the residual method as vendor specific objective evidence ( VSOE ) of fair value exists for the undelivered elements, but not for all of the delivered elements. The residual method requires revenue to be allocated to the undelivered elements based on the fair value of such elements, as indicated by VSOE. VSOE is based on the price charged when an element is sold separately. Healthcare providers also pay us fees for maintenance and support of their practice management system, including the hardware and software. We recognize revenue from these fees ratably over the contract period, typically in one year or less. Healthcare providers also pay us fees for transmitting

**Table of Contents**

transactions to payers and patients. We recognize revenue from these fees, which are generally billed on a monthly or per transaction basis, as we provide the service.

*Portal Services or WebMD Health.* Customers pay us for advertising, sponsorship, healthcare management tools, continuing medical education ( CME ), content syndication and distribution, and e-commerce transactions related to our online distribution channels and the online and offline distribution channels of our strategic partners. Revenue from advertising is recognized as advertisements are delivered. Revenues from sponsorship arrangements and healthcare management tools are recognized ratably over the term of the applicable agreement. Revenue from CME arrangements is recognized over the period we satisfy the minimum credit hour requirements of the applicable agreements. Revenue from fixed fee content license or carriage fees is recognized ratably over the term of the applicable agreement. E-commerce revenue is recognized when a subscriber or consumer utilizes our Internet-based services or purchases goods or services through our Web site or a co-branded Web site with one of our strategic partners. Subscription revenue, including subscription revenue from sponsorship arrangements, is recognized over the subscription period. When contractual arrangements contain multiple elements, revenue is allocated to the elements based on their relative fair values, determined using prices charged when elements are sold separately.

*Plastic Technologies or Porex.* We develop, manufacture and distribute porous and solid plastic products and components. For standard products, we recognize revenue upon shipment of product, net of sales returns and allowances. Reserves are established for anticipated returns and allowances based on past experience. For sales of certain custom products, we recognize revenue upon completion and customer acceptance. Amounts received in advance of meeting these criteria are deferred until we meet these criteria.

*Long-Lived Assets.* Our long-lived assets consist of property and equipment, goodwill and other intangible assets. Goodwill and other intangible assets arise from the acquisitions we have made. The amount assigned to intangible assets is subjective and based on our estimates of the future benefit of the intangible asset using accepted valuation techniques, such as discounted cash flow and replacement cost models. Our long-lived assets are amortized over their estimated useful lives, which we determined based on the consideration of several factors including the period of time the asset is expected to remain in service. We evaluate the carrying value and remaining useful lives of long-lived assets, excluding goodwill, whenever indicators of impairment are present. We evaluate the carrying value of goodwill annually. We use a discounted cash flow approach to determine the fair value of goodwill. There was no impairment of goodwill noted as a result of our impairment testing in 2002.

*Investments.* Our investments, at March 31, 2003, consist principally of certificates of deposit, municipal bonds, asset-backed securities, Federal Agency Notes, U.S. Treasury Notes and an equity investment in a publicly traded company. Each reporting period we evaluate the carrying value of our investments and record a loss on investments when we believe an investment has experienced a decline in value that is other than temporary. We do not recognize gains on an investment until sold. Our carrying value is not necessarily indicative of the underlying value of an investment. Future changes in market or economic conditions or operating results of our investments could result in gains or losses or an inability to recover the carrying value of the investments that may not be reflected in an investment's carrying value.

*Deferred Tax Assets.* Our deferred tax assets are comprised primarily of net operating loss carryforwards. These loss carryforwards may be used to offset taxable income in future periods reducing the amount of taxes we might otherwise be required to pay. Due to a lack of a history of generating taxable income, we record a valuation allowance equal to 100% of our net deferred tax assets. In the event that we are able to generate taxable earnings in the future and determine it is more likely than not that we can realize our deferred tax assets, an adjustment to the valuation

## **Table of Contents**

allowance would be made which may increase income in the period that such determination was made.

*Restructuring and Integration.* In connection with our restructuring and integration efforts, modifications to our strategic relationship with News Corporation resulted in a change in the carrying value of advertising services we have the rights to, classified as prepaid content and distribution services. We estimated the fair value of our rights under the new agreement using a discounted cash flow approach. This estimate also affects the amortization of this asset in future periods over the contractual term. Also, in connection with our restructuring and integration efforts, we recorded charges for estimated future lease obligations and lease cancellation penalties related to exited facilities based on many different variables, such as the term to expiration, contractual rights under the lease agreement and current real estate market conditions. Future changes in any of these variables, such as a change in real estate market conditions, could have an impact on these estimates.

### **Restructuring and Integration Initiatives**

After the mergers with Medical Manager Corporation, CareInsite, Inc. and OnHealth Network Company in September 2000, our Board of Directors approved a restructuring and integration plan, with the objective of eliminating duplication and redundancies that resulted from the acquisitions made by us since November 1999 and consolidating our operational infrastructure into a common platform to more efficiently serve our customers.

Additionally, as part of our restructuring and integration efforts, we also undertook a review of our existing strategic relationships in light of several criteria, including strategic relevance to both us and our partners, potential conflicts with other agreements as a result of the numerous acquisitions made by us, profitability and impact on future revenue streams. These reviews resulted in significant revisions to some of our strategic relationships. Our restructuring and integration efforts continued in 2001, and a plan to include the impact of eliminating functions resulting from our acquisition of Medscape in December 2001 was initiated. Additionally, our Plastic Technologies segment consolidated a manufacturing facility in 2002 as part of a separate restructuring plan.

We have substantially completed our restructuring and integration efforts, with the primary exception being remaining lease payments of previously vacated facilities.

### **Results of Operations**

Revenue is derived from our four business segments: Transaction Services, Physician Services, Portal Services and Plastic Technologies. Our Transaction Services include administrative services, such as transaction processing for medical, dental and pharmacy claims, automated patient statements and clinical lab and reporting services, such as lab test orders and results. A significant portion of Transaction Services revenues is generated from the country's largest national and regional healthcare payers. Our Physician Services include sales of practice management systems, including administrative, financial and clinical applications and services, under The Medical Manager, Intergy, ULTIA and Medical Manager Network Services brands. Portal Services include advertising, sponsorship, continuing medical education, content syndication and distribution, and e-commerce transactions through our online distribution channels and the online and offline distribution channels of our strategic partners. The majority of Portal Services revenues are derived from a small number of customers. Our customers include pharmaceutical companies, biotech companies, medical device companies and media companies. Our Plastic Technologies revenue includes the sale of porous plastic components used to control the flow of fluids and gases, disposable plastic components including pipette tips, test tubes and closure devices, injection-molded medical components and finished medical devices, and sterile surgical products.

Cost of operations consists of costs related to services and products we provide to customers and costs associated with the operation and maintenance of our networks. These costs include salaries and related expenses for network operations personnel and customer support personnel, telecommunication costs,

**Table of Contents**

maintenance of network equipment, cost of hardware related to the sale of practice management systems, a portion of facilities expenses, leased personnel and facilities costs, sales commissions paid to certain distributors of our Transaction Services products, and non-cash expenses related to content and distribution services. In addition, cost of operations includes raw materials, direct labor and manufacturing overhead, such as fringe benefits, indirect labor and product development related to our Plastic Technologies segment.

Development and engineering expense consists primarily of salaries and related expenses associated with the development of applications and services. Expenses include compensation paid to development and engineering personnel, fees to outside contractors and consultants, and the maintenance of capital equipment used in the development process.

Sales, marketing, general and administrative expense consists primarily of advertising, product and brand promotion, salaries and related expenses for sales, administrative, finance, legal, information technology, human resources and executive personnel. These expenses include items related to account management and marketing personnel, commissions, costs and expenses for marketing programs and trade shows, and fees for professional marketing and advertising services, as well as fees for professional services, costs of general insurance and costs of accounting and internal control systems to support our operations. Also included are non-cash expenses related to content and distribution services acquired in exchange for our equity securities and stock compensation expense primarily related to the amortization of deferred compensation. Content and distribution services consist of advertising, promotion and distribution services from our arrangements with News Corporation, Microsoft, AOL and other partners. Stock compensation is primarily related to deferred compensation associated with the intrinsic value of the unvested portion of stock options issued in exchange for outstanding stock options of companies we acquired in 2000, and the excess of the market price over the exercise price of certain options granted to employees.

The following discussion includes a comparison of the results of operations for the three months ended March 31, 2003 to the three months ended March 31, 2002.

*Consolidated*

*Revenue.* Revenues for the three months ended March 31, 2003 were \$234,743, compared to \$225,873 a year ago. Physician Services, Portal Services and Plastic Technologies segments were responsible for \$5,922, \$5,046 and \$997, respectively, of the revenue increase for the quarter, which was partially offset by a decrease in revenue of \$2,434 in Transaction Services and an increase of \$661 in inter-segment eliminations.

*Costs and Expenses*

*Cost of Operations.* Cost of operations decreased to \$134,380 for the three months ended March 31, 2003, compared to \$138,531 a year ago. Our cost of operations represented 57.2% of revenues for the three months ended March 31, 2003, compared to 61.3% for the three months ended March 31, 2002. This decrease was primarily due to the elimination of costs related to certain terminated products and relationships, such as hospital and laboratory connectivity relationships and consolidation of duplicate product offerings exited in May of 2002, as well as lower data communication costs in our Transaction Services segment. In addition, contributing to the decline, cost of operations for the three months ended March 31, 2003 does not include any non-cash expenses related to content and distribution services, compared to \$974 a year ago.

*Development and Engineering.* Development and engineering expense was \$11,012 for the three months ended March 31, 2003, which was relatively unchanged from \$10,868 a year ago.

*Sales, Marketing, General and Administrative.* Sales, marketing, general and administrative expense decreased 11.7% to \$70,070 for the three months ended March 31, 2003, compared to \$79,366 a year ago. Included in sales, marketing, general and administrative expense are non-cash expenses related to content and distribution services and stock compensation. Non-cash expenses related to content and distribution

## **Table of Contents**

services were \$6,146 for the three months ended March 31, 2003, compared to \$6,286 a year ago. This decrease was primarily due to the expiration of certain content and distribution alliance agreements. Non-cash stock compensation was \$3,757 for the three months ended March 31, 2003, compared to \$7,576 a year ago. The decrease in non-cash stock compensation is primarily related to the vesting schedules of options issued and assumed in connection with our 2000 acquisitions. Sales, marketing, general and administrative expense, excluding the non-cash expenses discussed above, decreased to \$60,167, or 25.6% of revenue, for the three months ended March 31, 2003, compared to \$65,504, or 29.0% of revenue, a year ago. This decrease is primarily due to lower cost associated with marketing efforts in our Portal Services segment.

*Depreciation and Amortization.* Depreciation and amortization expense decreased to \$27,976 for the three months ended March 31, 2003, compared to \$32,759 a year ago. The decrease was the result of intangible assets relating to certain acquisitions made in 1999 and 2000 becoming fully amortized.

*Restructuring and Integration Benefit.* Restructuring and integration benefit for the three months ended March 31, 2002 of \$3,750, related to a payment received in settlement of certain contractual obligations.

*Gain on Investments.* Gain on investments of \$183 primarily consists of a gain related to two of our investments in held-to-maturity securities that were called for early redemption during the quarter.

*Interest Income.* Interest income increased to \$5,055 during the three months ended March 31, 2003, compared to \$3,140 a year ago. This increase is due to higher investment balances, primarily related to the \$292,000 of net proceeds received from our issuance of 3 1/4% Convertible Subordinated Notes on April 1, 2002.

*Interest Expense.* Interest expense increased to \$2,921 for the three months ended March 31, 2003, compared to \$141 a year ago as a result of interest expense and amortization of debt issuance costs related to the 3 1/4% Convertible Subordinated Notes issued in April 2002.

*Income Tax Provision.* Income tax provision for the three months ended March 31, 2003 and 2002 includes tax expense for operations that are profitable in certain states and foreign countries. Accordingly, we provided for \$980 and \$700 of state, local and foreign income taxes for the three months ended March 31, 2003 and 2002, respectively.

### *Segments*

We have aligned our business into four operating segments as follows:

*Transaction Services or WebMD Envoy.* We transmit transactions between healthcare payers and physicians, pharmacies, dentists, hospitals, laboratory companies and other healthcare providers using dial-up, Internet and dedicated communication methods. We provide connectivity and transaction services through an integrated electronic transaction processing system. These services assist the group's customers in automating key administrative and clinical functions. In addition, Transaction Services provides automated patient billing services to providers, including statement printing and mailing services.

*Physician Services or WebMD Medical Manager.* We develop and market integrated physician practice management systems, including administrative, financial and clinical applications and services, under The Medical Manager, Intergy, ULTIA and Medical Manager Network Services brands. These systems and services allow physician offices to automate their scheduling, billing and other administrative tasks, to maintain electronic medical records and to automate documentation of patient encounters.

*Portal Services or WebMD Health.* We provide online healthcare information and related resources and services for consumers and healthcare professionals, both directly and through our relationships with leading general consumer Internet portals. We also provide online content for use by media and healthcare partners in their Web sites. We develop and sell online and offline

**Table of Contents**

programs for advertisers and sponsors, particularly those who are interested in influencing healthcare decisions.

*Plastic Technologies or Porex.* We develop, manufacture and distribute proprietary porous and solid plastic products and components used in healthcare, industrial and consumer applications, as well as in finished products used in medical device, research, clinical laboratory and surgical markets.

We evaluate the performance of our business segments based upon income or loss before restructuring, taxes, non-cash and other items. Non-cash and other items include depreciation, amortization, impairment charges, gain on investments, non-cash expenses related to content, advertising and distribution services acquired in exchange for our equity securities in acquisitions and strategic alliances, and stock compensation primarily related to stock options issued and assumed in connection with acquisitions. The accounting policies of the segments are the same as the accounting policies for the consolidated company. We record inter-segment revenues at rates comparable to those charged to third parties for comparable services.

Results for the three months ended March 31, 2003 and 2002 for each of our segments and a reconciliation to net loss is presented below:

|  | <b>Three Months Ended<br/>March 31,</b> |                    |
|--|---|--------------------|
|  | <b>2003</b>                             | <b>2002</b>        |
| <b>Revenues</b>  |   |                    |
| Transaction services   | \$ 115,493                              | \$ 117,927         |
| Physician services   | 72,011                                  | 66,089             |
| Portal services  | 22,180                                  | 17,134             |
| Plastic technologies   | 30,538                                  | 29,541             |
| Inter-segment eliminations   | (5,479)                                 | (4,818)            |
|  | <u>\$ 234,743</u>                       | <u>\$ 225,873</u>  |
| <b>Income (loss) before restructuring, taxes, non-cash and other items</b> |   |                    |
| Transaction services   | \$ 24,051                               | \$ 17,538          |
| Physician services   | 6,297                                   | 6,252              |
| Portal services  | 4,018                                   | (4,837)            |
| Plastic technologies   | 7,280                                   | 7,598              |
| Corporate  | (12,462)                                | (14,607)           |
| Interest income  | 5,055                                   | 3,140              |
| Interest expense   | (2,921)                                 | (141)              |
|  | <u>\$ 31,318</u>                        | <u>\$ 14,943</u>   |
| <b>Restructuring, taxes, non-cash and other items</b>                      |   |                    |
| Depreciation and amortization  | \$ (27,976)                             | \$ (32,759)        |
| Non-cash content and distribution services and stock compensation          | (9,903)                                 | (14,836)           |
| Restructuring and integration benefit                                      |   | 3,750              |
| Gain on investments  | 183                                     |                    |
| Income tax provision   | (980)                                   | (700)              |
|  | <u>\$ (7,358)</u>                       | <u>\$ (29,602)</u> |
| Net loss   | <u>\$ (7,358)</u>                       | <u>\$ (29,602)</u> |

The following discussion is a comparison of the results of operations for each of our operating segments for the three months ended March 31, 2003 to the three months ended March 31, 2002.



## Edgar Filing: WEBMD CORP /NEW/ - Form 10-Q

*Transaction Services.* Revenues were \$115,493 for the three months ended March 31, 2003, a decrease of \$2,434 compared to a year ago. This decrease is related to a reduction in revenues of \$5,574 associated with terminated laboratory connectivity products and relationships exited in May 2002. This

## **Table of Contents**

decrease was partially offset by increased revenue of \$3,140 related to higher transaction revenue and a postal rate increase that was effective July 1, 2002.

Income before restructuring, taxes, non-cash and other items was \$24,051 for the three months ended March 31, 2003, an increase of \$6,513 or 37.1%, compared to a year ago. As a percentage of revenue, income before restructuring, taxes, non-cash and other items improved to 20.8% for the three months ended March 31, 2003, compared to 14.9% a year ago. The improvement was primarily due to the elimination of costs associated with the terminated products and relationships discussed above and lower data communication costs.

*Physician Services.* Revenues were \$72,011 for the three months ended March 31, 2003, an increase of \$5,922, compared to a year ago. The increase is primarily attributable to higher maintenance revenues and Network Services revenues. The cumulative revenues from the 2002 and 2003 Acquisitions contributed \$2,472 of the increase in revenues.

Income before restructuring, taxes, non-cash and other items was \$6,297 for the three months ended March 31, 2003, an increase of \$45 compared to a year ago. As a percentage of revenue, income before restructuring, taxes, non-cash and other items was 8.7% for the three months ended March 31, 2003, compared to 9.5% a year ago. This decrease related to changes in the mix of revenues and roll-out costs related to our new products, primarily Intergy and our all payer/all transaction network services.

*Portal Services.* Revenues were \$22,180 for the three months ended March 31, 2003, an increase of \$5,046 compared to a year ago. The increase was primarily attributable to growth in our professional services products and to a lesser extent an increase in revenues from health plans and employers resulting from the products obtained in the 2002 Acquisitions.

Income before restructuring, taxes, non-cash and other items was \$4,018 for the three months ended March 31, 2003, compared to a loss of \$4,837 a year ago. As a percentage of revenue, the income (loss) before restructuring, taxes, non-cash and other items improved to 18.1% for the three months ended March 31, 2003, compared to (28.2)% a year ago. This improvement is the result of the increased revenues discussed above and reduced marketing related costs.

*Plastic Technologies.* Revenues were \$30,538 for the three months ended March 31, 2003, an increase of \$997 compared to a year ago. The increase was primarily due to higher sales of our porous, laboratory and surgical products, partially offset by lower sales of our injection molded medical products.

Income before restructuring, taxes, non-cash and other items was \$7,280 for the three months ended March 31, 2003, a decrease of \$318 compared to a year ago. As a percentage of revenue, income before restructuring, taxes, non-cash and other items was 23.8% for the three months ended March 31, 2003, compared to 25.7% a year ago. This decrease was due to higher sales and marketing expenses, partially offset by the increased sales discussed above.

*Corporate* includes expenses shared across all segments, such as executive personnel, corporate finance, legal, human resources and risk management costs. Corporate and other expenses declined to \$12,462 during the three months ended March 31, 2003 from \$14,607 a year ago, primarily as a result of reduced outside services expenses.

*Inter-Segment Eliminations.* The increase in inter-segment eliminations for the three months ended March 31, 2003, compared to a year ago, resulted from higher sales of Transaction Services products into the Physician Services customer base.

## **Liquidity and Capital Resources**

We have incurred significant operating and net losses since we began operations and, as of March 31, 2003, we had an accumulated deficit of \$10.2 billion. We plan to continue to invest in acquisitions, strategic relationships, infrastructure and product development.

**Table of Contents**

As of March 31, 2003, we had approximately \$466,928 in cash and cash equivalents and short-term investments and working capital of \$394,481. Additionally, we had long-term investments of \$218,602 in marketable debt securities and \$7,407 in marketable equity securities. We invest our excess cash principally in U.S. Treasury obligations and Federal Agency Notes and expect to do so in the future.

Cash provided by operating activities was \$33,950 for the three months ended March 31, 2003 compared to \$28,618 a year ago. The cash provided from operating activities was primarily a result of the net loss of \$7,358 for the three months ended March 31, 2003, offset by non-cash charges of \$38,254 and net changes in operating assets and liabilities of \$3,237. The positive impact of changes in operating assets and liabilities may reverse in future periods, depending on the timing of each period end in relation to items such as internal payroll and billing cycles, payments from customers, payments to vendors, interest payments relating to our 3 1/4% Convertible Subordinated Notes and interest receipts relating to our investments in marketable securities. The cash provided by operating activities a year ago was primarily attributable to a net loss of \$29,602, offset by non-cash charges of \$47,595 and net changes in operating assets and liabilities of \$10,625. The non-cash charges consist of depreciation and amortization, non-cash expenses related to content and distribution services and stock compensation and amortization of debt issuance costs.

Cash provided by investing activities was \$22,071 for the three months ended March 31, 2003, compared to cash used in investing activities of \$83,306 a year ago. Cash provided by investing activities for the three months ended March 31, 2003 primarily related to \$102,720 of proceeds from the maturities, and redemptions of available-for-sale and held-to-maturity securities, partially offset by \$76,283 of purchases of held-to-maturity and available-for-sale securities. Cash used in investing activities a year ago primarily related to purchases of held-to-maturity securities, partially offset by maturities of available-for-sale securities. Investments in property and equipment were \$4,022 and \$5,753 for the three months ended March 31, 2003 and 2002, respectively.

Cash provided by financing activities was \$16,913 for the three months ended March 31, 2003, compared to cash used in financing activities of \$5,294 a year ago. Cash provided by financing activities for the three months ended March 31, 2003 principally relates to net proceeds of \$17,025 related to exercises of employee stock options. Cash used in financing activities a year ago, primarily related to \$10,000 used to redeem our Series B Preferred Stock, which was partially offset by net proceeds of \$5,351 from exercises of employee stock options.

As of March 31, 2003, we did not have any material commitments for capital expenditures. Our principal commitments, at March 31, 2003, consisted primarily of our commitments related to the \$300 million of 3 1/4% Convertible Subordinated Notes due in April 2007, obligations under operating leases and guaranteed payments under our strategic agreements. We had entered into agreements that provided for us to make aggregate guaranteed payments in the following estimated amounts, net of sublease income, under operating leases and our strategic relationships. The lease amounts include leases identified in our restructuring and integration efforts.

| Year Ending December 31, | Leases | Strategic Relationships | Total  |
|--------------------------|--------|-------------------------|--------|
|                          |        | (in millions)           |        |
| 2003                     | 25,901 | 2,501                   | 28,402 |
| 2004                     | 23,198 | 1,262                   | 24,460 |
| 2005                     | 19,097 | 754                     | 19,851 |
| 2006                     | 15,662 | 500                     | 16,162 |
| 2007                     | 13,749 | 125                     | 13,874 |
| Thereafter               | 45,229 |                         | 45,229 |

We believe that we will have sufficient cash resources to meet our obligations related to our \$300 million of 3 1/4% Convertible Subordinated Notes and our presently anticipated working capital and capital expenditure requirements, including the capital requirements related to the roll-out of our new products in 2003, for the foreseeable future. Our future liquidity and capital requirements will depend upon numerous

**Table of Contents**

factors, including the success of the integration of our businesses, retention of customers at current volume and revenue levels, our existing and new application and service offerings, competing technological and market developments, potential future acquisitions and additional repurchases of our common stock. In addition, we have been incurring, and expect to continue to incur, costs relating to our own compliance with the Healthcare Insurance Portability and Accountability Act of 1996, or HIPAA, and for assistance we provide to our customers in their compliance efforts. Our ability to perform our services in compliance with HIPAA and the cost to us of doing so will depend on, among other things, the status of the compliance efforts of our payer and provider customers and the extent of the need to adjust our systems and procedures in response to changes in their systems and procedures. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. There can be no assurance that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders.

**Recent Accounting Pronouncements**

In December 2002, the FASB issued Statement of Financial Accounting Standards No. 148 ( SFAS No. 148 ), Accounting for Stock-Based Compensation Transition and Disclosure An Amendment of FASB Statement No. 123. The statement provides alternative methods of transition for a voluntary change to the fair value method of accounting for stock-based employee compensation. In addition, the statement requires us to disclose, in both annual and interim financial statements, the method of accounting for stock-based compensation and the effect of the method used on our reported results. The statement is effective for annual periods ending after December 15, 2002 and interim periods beginning after December 15, 2002. We apply the intrinsic value method of accounting for stock-based employee compensation. The adoption of SFAS No. 148 did not have a material impact on our consolidated financial position or results of operations.

In November 2002, the FASB issued Interpretation No. 45, Guarantor s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others ( FIN 45 ). The interpretation elaborates on the disclosures to be made in our interim and annual financial statements about obligations under certain guarantees. It also requires us to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The disclosure requirements are effective for financial statements of interim and annual periods ending after December 15, 2002. The initial measurement and recognition provisions are required to be applied on a prospective basis to guarantees issued or modified after December 31, 2002. The adoption of FIN 45 did not have any impact on our consolidated financial position or results of operations.

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. SFAS No. 146 requires recording costs associated with exit or disposal activities at their fair values when a liability has been incurred. Under previous guidance, certain exit costs were accrued upon management s commitment to an exit plan, which is generally before an actual liability has been incurred. SFAS No. 146 is effective for exit or disposal activities initiated after December 31, 2002. SFAS No. 146 will have an impact on the timing of the recording of any future restructuring charges.

In August 2001, the FASB issued SFAS No. 144, Accounting For Impairment of Long-Lived Assets. We adopted this pronouncement beginning January 1, 2002. SFAS No. 144 prescribes the accounting for long-lived assets (excluding goodwill) to be disposed of by sale. SFAS No. 144 retains the requirement of SFAS No. 121 to measure long-lived assets classified as held for sale at the lower of its carrying value or fair market value less the cost to sell. Therefore, discontinued operations are no longer measured on a net realizable basis, and future operating results are no longer recognized before they occur. The adoption of SFAS No. 144 did not have any impact on our consolidated financial condition or results of operations.

## **Table of Contents**

In June 2001, the FASB issued SFAS No. 143, Accounting for Asset Retirement Obligations, which establishes accounting standards for recognition and measurement of a liability for the costs of asset retirement obligations. Under SFAS No. 143, the future costs of retiring a tangible long-lived asset will be recorded as a liability at its present value when the retirement obligation arises, and will be amortized to expense over the life of the asset. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. The adoption of SFAS No. 143 did not have any impact on our consolidated financial position or results of operations.

## **Factors That May Affect Our Future Financial Condition or Results of Operations**

This section describes circumstances or events that could have a negative effect on our financial results or operations or that could change, for the worse, existing trends in some or all of our businesses. The occurrence of one or more of the circumstances or events described below could have a material adverse effect on our financial condition, results of operations and cash flows or on the trading prices of the common stock and convertible notes that we have issued. The risks and uncertainties described below are not the only ones facing WebMD. Additional risks and uncertainties that are not currently known to us or that we currently believe are immaterial may also adversely affect our business and operations.

---

### **Risks Related to Our Relationships with Customers and Strategic Partners**

*WebMD Envoy's transaction volume and financial results could be adversely affected if we do not maintain relationships with practice management system vendors and large submitters of healthcare EDI transactions*

We have developed relationships with practice management system vendors and large submitters of healthcare claims to increase the usage of our WebMD Envoy transaction services. WebMD Medical Manager is a competitor of these practice management system vendors. These vendors, as a result of our ownership of WebMD Medical Manager or for other reasons, may choose in the future to diminish or terminate their relationships with WebMD Envoy. Some other large submitters of claims compete with, or may have significant relationships with entities that compete with, WebMD Envoy or WebMD Health. To the extent that we are not able to maintain mutually satisfactory relationships with the larger practice management system vendors and large submitters of healthcare EDI transactions, WebMD Envoy's transaction volume and financial results could be adversely affected.

*WebMD Envoy's transaction volume and financial results could be adversely affected if payers and providers conduct EDI transactions without using a clearinghouse*

There can be no assurance that healthcare payers and providers will continue to use WebMD Envoy and other independent companies to transmit healthcare transactions. Some payers currently offer electronic data transmission services to healthcare providers that establish a direct link between the provider and payer, bypassing third party EDI service providers such as WebMD Envoy. Any significant increase in the utilization of direct links between healthcare providers and payers could have a material adverse effect on WebMD Envoy's transaction volume and financial results. We cannot provide assurance that we will be able to maintain our existing links to payers or develop new connections on satisfactory terms, if at all.

*Loss of a small number of advertisers and sponsors could have a material adverse effect on WebMD Health's revenues*

A substantial portion of WebMD Health's revenues come from a relatively small number of advertisers and sponsors. We expect this to continue in the future. Thus, the loss of one or a small number of relationships with advertisers and sponsors or reduction of their purchases could have a material adverse effect on our Portal Services revenues. We may lose such relationships or experience a reduction in purchases if customers decide not to renew their commitments or renew at lower levels, which may occur

**Table of Contents**

if we fail to meet our customers' expectations or needs or fail to keep up with our competition or for reasons outside our control, including changes in economic and regulatory conditions affecting the healthcare industry or changes specific to the businesses of particular customers. For more information, see "Risks Related to Providing Products and Services to the Healthcare Industry" below and "Business - Government Regulation" in our 2002 Annual Report on Form 10-K.

*Third parties may bring claims as a result of the activities of our strategic partners*

We could be subject to claims by third parties, and to liability, as a result of the activities, products or services of our strategic partners. We state on our Web sites that we do not control or endorse the products or services of our strategic partners. However, there can be no assurance that the statements made in our portal will be found to be sufficient to ensure that we are not held responsible for such activities, products or services. Furthermore, even if these claims do not result in liability to us, investigating and defending these claims could be expensive, time-consuming and result in adverse publicity that could harm our business.

---

**Risks Related to the Performance of Our  
Healthcare Information Services and Technology Solutions**

*Our ability to generate revenue could suffer if we do not continue to update and improve our existing products and services and develop new ones*

We must introduce new healthcare information services and technology solutions and improve the functionality of our existing products and services in a timely manner in order to retain existing customers and attract new ones. However, we may not be successful in responding to technological developments and changing customer needs. The pace of change in the markets we serve is rapid, and there are frequent new product and service introductions by our competitors and by vendors whose products and services we use in providing our own products and services. If we do not respond successfully to technological changes and evolving industry standards, our products and services may become obsolete. Technological changes may also result in the offering of competitive products and services at lower prices than we are charging for our products and services, which could result in our losing sales unless we lower the prices we charge.

We rely on a combination of internal development, strategic relationships, licensing and acquisitions to develop our products and services. The cost of developing new healthcare information services and technology solutions is inherently difficult to estimate. Our development of proposed products and services may take longer than originally expected, require more testing than originally anticipated and require the acquisition of additional personnel and other resources. In addition, there can be no assurance that the products we develop or license will be able to compete with the alternatives available to our customers. For more information about the competition we face, see "Business - Healthcare Information Services and Technology Solutions - Competition for Our Healthcare Information Services and Technology Solutions" in our 2002 Annual Report on Form 10-K.

*New or newly integrated products and services will not become profitable unless they achieve sufficient levels of market acceptance*

There can be no assurance that healthcare providers and payers will accept from us new products and services or products and services that result from integrating existing and/or acquired products and services, including the products and services we are developing to integrate our transaction services and portal services into the physician office workflow, such as our handheld solution.

Even providers and payers who are already our customers may not purchase new or newly integrated products or services, especially when they are initially offered. Providers using our existing products and services may refuse to adopt new or newly integrated products and services when they have made extensive investments in hardware, software and training relating to those existing products and services. Similarly,

**Table of Contents**

other healthcare participants may not accept new or newly integrated products and services that we develop for their use. In addition, there can be no assurance that any pricing strategy that we implement for any such products and services will be economically viable or acceptable to the target markets. Failure to achieve broad penetration in target markets with respect to new or newly integrated products and services could have a material adverse effect on our business prospects.

*Achieving market acceptance of new or newly integrated products and services is likely to require significant efforts and expenditures*

Achieving market acceptance for new or newly integrated products and services is likely to require substantial marketing efforts and expenditure of significant funds to create awareness and demand by participants in the healthcare industry. In addition, deployment of new or newly integrated products and services may require the use of additional resources for training our existing sales force and customer service personnel and for hiring and training additional salespersons and customer service personnel. There can be no assurance that the revenue opportunities from new or newly integrated products and services will justify amounts spent for their development, marketing and roll-out.

*We could be subject to breach of warranty claims if our software products, information technology systems or transmission systems contain errors, experience failures or do not meet customer expectations*

We could face breach of warranty or other claims or additional development costs if the software and systems we sell or license to customers or use to provide services contain undetected errors, experience failures, do not perform in accordance with their documentation, or do not meet the expectations that our customers have for them. These software and systems are inherently complex and, despite testing and quality control, we cannot be certain that errors will not be found in prior versions, current versions or future versions or enhancements. In particular, during times when we are making significant changes or improvements to our products and services, such as those required by HIPAA, there is increased risk of error.

Undetected errors in the software and systems we provide or those we use to provide services could cause serious problems for which our customers may seek compensation from us. For example, errors in our transaction processing systems can result in healthcare payers paying the wrong amount or making payments to the wrong payee. We attempt to limit, by contract, our liability for damages arising from negligence, errors or mistakes. However, contractual limitations on liability may not be enforceable in certain circumstances or may otherwise not provide sufficient protection to us from liability for damages. Even if these claims do not result in liability to us, investigating and defending against them could be expensive and time consuming and could divert management's attention away from our operations. In addition, negative publicity caused by these events may delay market acceptance of our products and services, including unrelated products and services.

*We could be subject to product liability claims if our products malfunction or provide inaccurate information*

We provide products and services that assist in healthcare decision-making, including some that relate to patient medical histories and treatment plans. If these products malfunction or fail to provide accurate and timely information, we could be subject to product liability claims. Even if these claims do not result in liability to us, investigating and defending against them could be expensive and time consuming and could divert management's attention away from our operations. In addition, negative publicity caused by these events may delay market acceptance of our products and services, including unrelated products and services.

We attempt to limit, by contract, our liability for damages arising from negligence, errors or mistakes. However, contractual limitations on liability may not be enforceable in certain circumstances or may otherwise not provide sufficient protection to us from liability for damages. We maintain general liability insurance coverage, including coverage for errors and omissions. However, it is possible that claims could

**Table of Contents**

exceed the amount of our applicable insurance coverage or that this coverage may not continue to be available on acceptable terms or in sufficient amounts.

*We could lose customers and revenues if we fail to meet the performance standards in our contracts*

Many of our customer contracts contain performance standards. If we fail to meet these standards, our customers may seek to terminate their agreements with us, withhold payments due to us, seek refunds from us of part or all of the fees charged under those agreements or initiate litigation or other dispute resolution procedures. Despite testing and quality control, we cannot be certain that we will meet these performance standards. To the extent we fail to achieve these standards, our revenues and customer relationships could be adversely affected.

*If our systems or the Internet experience security breaches or are otherwise perceived to be insecure, our business could suffer*

A security breach could damage our reputation or result in liability. We retain and transmit confidential information, including patient health information, in our processing centers and other facilities. It is critical that these facilities and infrastructure remain secure and be perceived by the marketplace as secure. We may be required to expend significant capital and other resources to protect against security breaches and hackers or to alleviate problems caused by breaches. Despite the implementation of security measures, this infrastructure or other systems that we interface with, including the Internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, attacks by third parties or similar disruptive problems. Any compromise of our security, whether as a result of our own systems or systems that they interface with, could reduce demand for our services.

*Performance problems with WebMD Envoy's systems could adversely affect our business*

Our payer and provider customer satisfaction and our business could be harmed if WebMD Envoy experiences delays, failures or loss of data in its systems. We currently process our payer and provider transactions and data at our facilities and at a data center in Tampa, Florida that is operated by an independent third party. We have contingency plans for emergencies with our systems; however, we have limited backup facilities to process information if these facilities are not functioning. The occurrence of a major catastrophic event or other system failure at any of our facilities or at the third party facility could interrupt data processing or result in the loss of stored data, which could have a material adverse impact on our business.

*WebMD Envoy's ability to provide transaction services depends on services provided by telecommunications companies*

WebMD Envoy relies on a limited number of suppliers to provide some of the telecommunications services necessary for its transaction services. The telecommunications industry has been subject to significant changes as a result of changes in technology, regulation and the underlying economy. Recently, many telecommunications companies have experienced financial problems and some have sought bankruptcy protection. Some of these companies have discontinued telecommunications services for which they had contractual obligations to WebMD Envoy. WebMD Envoy's inability to source telecommunications services at reasonable prices due to a loss of competitive suppliers could affect its ability to maintain its margins until it is able to raise its prices to its customers and, if it is not able to raise its prices, could have a material adverse effect on its financial results.



**Table of Contents**

**Risks Related to Providing Products and Services to the Healthcare Industry**

*Developments in the healthcare industry could adversely affect our business*

Almost all of the revenues of WebMD Health, WebMD Envoy and WebMD Medical Manager come from customers in various parts of the healthcare industry. In addition, a significant portion of Porex's revenues come from products used in healthcare or related applications. Developments that result in a reduction of expenditures by customers or potential customers in the healthcare industry could have a material adverse effect on our business. General reductions in expenditures by healthcare industry participants could result from, among other things:

government regulation or private initiatives that affect the manner in which healthcare providers interact with patients, payers or other healthcare industry participants, including changes in pricing or means of delivery of healthcare products and services (for additional discussion of the potential effects of regulatory matters on our business and on participants in the healthcare industry, see *Business Government Regulation* in our 2002 Annual Report on Form 10-K);

consolidation of healthcare industry participants;

reductions in governmental funding for healthcare; and

adverse changes in business or economic conditions affecting healthcare payers or providers, pharmaceutical companies, medical device manufacturers or other healthcare industry participants.

Even if general expenditures by industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending on information technology and services or in some or all of the specific segments of that market we serve or are planning to serve. For example, use of our products and services could be affected by:

changes in the billing patterns of healthcare providers;

changes in the design of health insurance plans;

changes in the contracting methods payers use in their relationships with providers; and

decreases in marketing expenditures by pharmaceutical companies or medical device manufacturers, including as a result of governmental regulation or private initiatives that discourage or prohibit promotional activities by pharmaceutical or medical device companies.

In addition, expectations of our customers regarding pending or potential industry developments may also affect their budgeting processes and spending plans with respect to products and services of the types we provide.

The healthcare industry has changed significantly in recent years and we expect that significant changes will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. We cannot provide assurance that the markets for our products and services will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in those markets.

*Government regulation of healthcare and healthcare information technology, including HIPAA, creates risks and challenges with respect to our compliance efforts and our business strategies*

*General.* The healthcare industry is highly regulated and is subject to changing political, regulatory and other influences. These factors affect the purchasing practices and operations of healthcare organizations. Federal and state legislatures and agencies periodically consider programs to reform or revise the United States healthcare system. These programs may contain proposals to increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the environment in which healthcare industry participants operate. Healthcare industry participants may respond by reducing their investments or postponing investment decisions, including investments in our applications and services. We

## **Table of Contents**

are unable to predict future proposals with any certainty or to predict the effect they would have on our business. Existing laws and regulations also could create liability, cause us to incur additional costs or restrict our operations.

*HIPAA.* As described under *Business Government Regulation* and *WebMD Envoy HIPAA* in our 2002 Annual Report on Form 10-K, the effect of HIPAA on our business is difficult to predict and there can be no assurances that we will adequately address the business risks created by HIPAA and its implementation or that we will be able to take advantage of any resulting business opportunities. We may incur significant expenses relating to compliance with HIPAA. Our ability to perform our transaction services in compliance with HIPAA and the cost to us of doing so will depend on, among other things, the status of the compliance efforts of our payer and provider customers and the extent of the need to adjust our systems and procedures in response to changes in their systems and procedures. We cannot control when or how payers, providers, practice management system vendors or other healthcare participants will comply with HIPAA's transaction standards or predict how their compliance efforts will affect their relationships with us, including the volume of transactions for which they use our services. In addition, our technological and strategic responses to HIPAA may result in conflicts with, or other adverse changes in our relationships with, some healthcare industry participants, including some who are existing or potential customers for our products and services or existing or potential strategic partners. Furthermore, we are unable to predict what changes to HIPAA, or the regulations issued pursuant to HIPAA, might be made in the future or how those changes could affect our business or the costs of compliance with HIPAA.

*Healthcare Relationships.* A federal law commonly known as the Medicare/Medicaid anti-kickback law and several similar state laws prohibit payments that are intended to induce healthcare providers either to refer patients or to acquire or arrange for or recommend the acquisition of healthcare products or services. These laws are broad and may apply to some of our activities or our relationships with our customers, advertisers or strategic partners. Other federal and state laws generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or are for items or services that were not provided as claimed. Since we provide transaction services to healthcare providers, we cannot provide assurance that the government will regard errors in transactions processed by us as inadvertent and not in violation of these laws. Anti-kickback and false claims laws prescribe civil and criminal penalties for noncompliance that can be substantial. Even an unsuccessful challenge by regulatory authorities of our practices could cause us adverse publicity and be costly for us to respond to.

*Regulation of Medical Devices.* Certain of Porex's products are FDA-regulated medical devices, such as plastic and reconstructive surgical implants, intravenous administration sets, blood filters, and tissue expanders. These products are subject to comprehensive government regulation under the Food, Drug and Cosmetic Act and implementing regulations. In addition, the FDA regulates WebMD Medical Manager's DIM<sub>DX</sub> System as a medical image management device. If the FDA were to find that we have not complied with required procedures, it can bring a wide variety of enforcement actions that could result in severe civil and criminal sanctions. Porex is also subject to similar regulation in international markets, with similar risks. Future products that we wish to bring to market may require clearances or approvals from governmental authorities, which may be expensive, time-consuming and burdensome to obtain.

For more information regarding healthcare regulation to which we are or may be subject, see *Business Government Regulation* in our 2002 Annual Report on Form 10-K.

---

### **Risks Related to Our Web Sites and Our Use of the Internet**

*Government regulation of the Internet could adversely affect our business*

The Internet and its associated technologies are subject to government regulation. Our failure, or the failure of our business partners, to accurately anticipate the application of applicable laws and regulations,

**Table of Contents**

or any other failure to comply, could create liability for us, result in adverse publicity, or negatively affect our business. In addition, new laws and regulations, or new interpretations of existing laws and regulations, may be adopted with respect to the Internet or other online services covering user privacy, patient confidentiality, consumer protection and other issues, including pricing, content, copyrights and patents, distribution, and characteristics and quality of products and services. We cannot predict whether these laws or regulations will change or how such changes will affect our business. Government regulation of the Internet could limit the effectiveness of the Internet for the methods of healthcare e-commerce that we are providing or developing or even prohibit the sale of particular products and services.

For more information regarding government regulation of the Internet to which we are or may be subject, see **Business Government Regulation** in our 2002 Annual Report on Form 10-K.

*We face potential liability related to the privacy and security of personal information we collect on our Web sites*

Internet user privacy has become a controversial issue both in the United States and abroad. We have privacy policies posted on our consumer portal and our professional portal that we believe comply with applicable laws requiring notice to users about our information collection, use and disclosure practices. However, whether and how existing privacy and consumer protection laws in various jurisdictions apply to the Internet is still uncertain and may take years to resolve. Any legislation or regulation in the area of privacy of personal information could affect the way we operate our Web sites and could harm our business. Further, we can give no assurance that the statements on our portals, or our practices, will be found sufficient to protect us from liability or adverse publicity in this area.

For more information regarding regulation of the collection, use and disclosure of personal information to which we may be subject, see **Business Government Regulation** in our 2002 Annual Report on Form 10-K.

*We must demonstrate the value of the WebMD Medscape Health Network to advertisers and sponsors in order to generate revenue from it*

We generate WebMD Health revenues from advertising and sponsorships on the WebMD Medscape Health Network, with a majority of these revenues coming from a small number of customers. The Internet advertising and sponsorship market is new and continues to evolve, and no standards have been widely accepted to measure its effectiveness as compared to traditional media advertising. We cannot provide assurance that we will be able to continue to generate sufficient advertising or sponsorship revenue from the WebMD Medscape Health Network to operate it profitably.

We sometimes enter into relationships with advertisers and sponsors in which we agree to be compensated based on specific negotiated criteria designed to demonstrate the value of our portal services. The amount of compensation that we receive from such arrangements may be less than we believed it would be at the time of entering into such arrangements and at the time of performing the services.

*Implementation of changes in hardware and software platforms used to deliver our Web sites may result in performance problems*

From time to time, we implement changes to the hardware and software platforms we use for creating and delivering our Web sites. During and after the implementation of those changes, a platform may not perform as expected, which could result in interruptions in the operation of our Web sites, an increase in response time of those sites or an inability to track performance metrics. Any significant interruption in our ability to operate our Web sites could have an adverse effect on our relationship with users and sponsors and, as a result, on our financial results.

**Table of Contents**

*Our Internet-based services rely on third party service providers*

Our Web sites are designed to operate 24 hours a day, seven days a week, without interruption. To do so, we rely on communications and hosting services provided by third parties. We do not maintain redundant systems or facilities for some of these services. To operate without interruption, both we and our service providers must guard against:

- damage from fire, power loss and other natural disasters;
- communications failures;
- software and hardware errors, failures or crashes;
- security breaches, computer viruses and similar disruptive problems; and
- other potential interruptions.

We have experienced periodic system interruptions in the past, and we cannot guarantee that they will not occur again. In addition, our Web sites may, at times, be required to accommodate higher than usual volumes of traffic. At those times, our Web sites may experience slower response times or system failures. Any sustained or repeated interruptions or disruptions in these systems or increase in their response times could result in reduced usage of our Web sites and could damage our relationships with strategic partners, advertisers and sponsors. Although we maintain insurance for our business, we cannot guarantee that our insurance will be adequate to compensate us for all losses that may occur or to provide for costs associated with business interruptions.

*Our Internet-based services are dependent on the development and maintenance of the Internet infrastructure*

Our ability to deliver our Internet-based services is dependent on the development and maintenance of the infrastructure of the Internet by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity and security, as well as timely development of complementary products such as high-speed modems, for providing reliable Internet access and services. The Internet has experienced, and is likely to continue to experience, significant growth in the number of users and the amount of traffic. If the Internet continues to experience increased usage, the Internet infrastructure may be unable to support the demands placed on it. In addition, the performance of the Internet may be harmed by increased usage.

The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services. In addition, our customers who utilize our Web-based services depend on Internet service providers, online service providers and other Web site operators for access to our Web site. All of these providers have experienced significant outages in the past and could experience outages, delays and other difficulties in the future due to system failures unrelated to our systems. Any significant interruptions in our services or increases in response time could result in a loss of potential or existing users of and advertisers and sponsors on our Web site and, if sustained or repeated, could reduce the attractiveness of our services.

*Third parties may challenge the enforceability of our online agreements*

The law governing the validity and enforceability of online agreements and other electronic transactions is evolving. We could be subject to claims by third parties that our online agreements with consumers and physicians that provide the terms and conditions for use of our portal services and physician services are unenforceable. A finding by a court that these agreements are invalid could harm our business and require costly changes to our portals.

**Table of Contents**

*Third parties may bring claims against us as a result of content provided on our Web sites, which may be expensive and time consuming to defend*

We could be subject to third party claims based on the nature and content of information supplied on our Web sites by us or third parties, including content providers, medical advisors or users. We could also be subject to liability for content that may be accessible through our Web sites or third party Web sites linked from our Web sites or through content and information that may be posted by users in chat rooms, bulletin boards or on Web sites created by professionals using our Web site application. Even if these claims do not result in liability to us, investigating and defending against these claims could be expensive and time consuming and could divert management's attention away from our operations.

*Some of our services will not be widely adopted until broadband connectivity is more generally available*

Some of our services and planned services require a continuous broadband connection between the physician's office and our data center and/or the Internet. The availability of broadband connectivity varies widely from location to location and even within a single geographic area, due to factors such as the distance of a site from the central switching office. The future availability of broadband connections is unpredictable and is not within our control. While we expect that many physician office locations will remain without ready access to broadband connectivity for some period of time, we cannot predict how long that will be. Accordingly, the lack of these broadband connections will continue to place limitations on the number of sites that are able to utilize some of our Internet-based services and the revenue we can expect to generate from those services.

---

**Risks Related to Porex's Business and Industry**

*Porex's success depends upon demand for its products, which in some cases ultimately depends upon end-user demand for the products of its customers*

Demand for our Porex products may change materially as a result of economic or market conditions and other trends that affect the industries in which it participates. In addition, because a significant portion of our Porex products are components that are eventually integrated into or used with products manufactured by customers for resale to end-users, the demand for these product components is dependent on product development cycles and marketing efforts of these other manufacturers, as well as variations in their inventory levels, which are factors that we are unable to control. Accordingly, the amount of Porex's sales to manufacturer customers can be difficult to predict and subject to wide quarter-to-quarter variances.

*Porex's success may depend upon satisfying rapidly changing customer requirements*

A significant portion of our Porex products are integrated into end products used in various industries, some of which are characterized by rapidly changing technology, evolving industry standards and practices and frequent new product introductions. Accordingly, Porex's success will depend to a substantial degree on our ability to develop and introduce in a timely manner products that meet changing customer requirements and to differentiate our offerings from those of our competitors. If we do not introduce new Porex products in a timely manner and make enhancements to existing products to meet the changing needs of our Porex customers, some of our products could become obsolete over time, in which case our customer relationships, revenue and operating results would be negatively impacted.

*Potential new or enhanced Porex products may not achieve sufficient sales to be profitable or justify the cost of their development*

We cannot be certain, when we engage in Porex research and development activities, whether potential new products or product enhancements will be accepted by the customers for which they are intended. Achieving market acceptance for new or enhanced products may require substantial marketing efforts and expenditure of significant funds to create awareness and demand by potential customers. In

**Table of Contents**

addition, sales and marketing efforts with respect to these products may require the use of additional resources for training our existing Porex sales forces and customer service personnel and for hiring and training additional salespersons and customer service personnel. There can be no assurance that the revenue opportunities from new or enhanced products will justify amounts spent for their development and marketing. In addition, there can be no assurance that any pricing strategy that we implement for any new or enhanced Porex products will be economically viable or acceptable to the target markets.

*Porex may not be able to source the raw materials it needs or may have to pay more for those raw materials*

Some of Porex's products require high-grade plastic resins with specific properties as raw materials. While Porex has not experienced any material difficulty in obtaining adequate supplies of high-grade plastic resins that meet its requirements, it relies on a limited number of sources for some of these plastic resins. If Porex experiences a reduction or interruption in supply from these sources, it may not be able to access alternative sources of supply within a reasonable period of time or at commercially reasonable rates, which could have a material adverse effect on its business and financial results.

Porex also uses a variety of plastic resins that are generally available from a number of suppliers. However, the raw materials for these plastic resins are petroleum based and may be subject to significant and rapid price increases based on factors affecting the pricing of petroleum products in general, which could have a material adverse effect on the margins of some of our plastic products.

*Disruptions in Porex's manufacturing operations could have a material adverse effect on its business and financial results*

Any significant disruption in Porex's manufacturing operations, including as a result of fire, power interruptions, equipment malfunctions, labor disputes, material shortages, earthquakes, floods, computer viruses, sabotage, terrorist acts or other force majeure, could have a material adverse effect on Porex's ability to deliver products to customers and, accordingly, its financial results.

*The nature of Porex's products exposes it to product liability claims that may not be adequately covered by indemnity agreements or insurance*

The products sold by Porex, whether sold directly to end-users or sold to other manufacturers for inclusion in the products that they sell, expose it to potential risk of product liability claims, particularly with respect to Porex's life sciences, clinical, surgical and medical products. Some of Porex's products are designed to be permanently implanted in the human body. Design defects and manufacturing defects with respect to such products sold by Porex or failures that occur with the products of Porex's manufacturer customers that contain components made by Porex could result in product liability claims and/or a recall of one or more of Porex's products. Porex also manufactures products that are used in the processing of blood for medical procedures and the delivery of medication to patients. Porex believes that it carries adequate insurance coverage against product liability claims and other risks. We cannot assure you, however, that claims in excess of Porex's insurance coverage will not arise. In addition, Porex's insurance policies must be renewed annually. Although Porex has been able to obtain adequate insurance coverage at an acceptable cost in the past, we cannot assure you that Porex will continue to be able to obtain adequate insurance coverage at an acceptable cost.

In most instances, Porex enters into indemnity agreements with its manufacturing customers. These indemnity agreements generally provide that these customers would indemnify Porex from liabilities that may arise from the sale of their products that incorporate Porex components to, or the use of such products by, end-users. While Porex generally seeks contractual indemnification from its customers, any such indemnification is limited, as a practical matter, to the creditworthiness of the indemnifying party. If Porex does not have adequate contractual indemnification available, product liability claims, to the extent not covered by insurance, could have a material adverse effect on its business, operating results and financial condition.

**Table of Contents**

Since March 1991, Porex has been named as one of many co-defendants in a number of actions brought by recipients of mammary implants distributed by Porex in the United States. For a description of these actions, see the information under Legal Proceedings Porex Mammary Implant Litigation in our 2002 Annual Report on Form 10-K.

*Economic, political and other risks associated with Porex's international sales and geographically diverse operations could adversely affect Porex's operations and results*

Since Porex sells its products worldwide, its business is subject to risks associated with doing business internationally. In addition, Porex has manufacturing assets in the United Kingdom, Germany and Malaysia. Accordingly, Porex's operations and financial results could be harmed by a variety of factors, including:

changes in foreign currency exchange rates;

changes in a specific country's or region's political or economic conditions, particularly in emerging markets;

trade protection measures and import or export licensing requirements;

potentially negative consequences from changes in tax laws;

difficulties in managing international and geographically diverse operations;

differing protection of intellectual property; and

unexpected changes in regulatory requirements.

*Environmental regulation could adversely affect Porex's business*

Porex is subject to foreign and domestic environmental laws and regulations and is subject to scheduled and random checks by environmental authorities. Porex's business involves the handling, storage and disposal of materials that are classified as hazardous. Although Porex's safety procedures for handling, storage and disposal of these materials are designed to comply with the standards prescribed by applicable laws and regulations, Porex may be held liable for any environmental damages that result from Porex's operations. Porex may be required to pay fines, remediation costs and damages, which could have a material adverse effect on its results of operations.

---

**Risks Applicable to Our Entire Company**

*We face significant competition for our products and services*

The markets in which we operate are intensely competitive, continually evolving and, in some cases, subject to rapid technological change. Many of our competitors have greater financial, technical, product development, marketing and other resources than we do. These organizations may be better known than we are and have more customers than we do. We cannot provide assurance that we will be able to compete successfully against these organizations or any alliances they have formed or may form. For more information about the competition we face, see Business Healthcare Information Services and Technology Solutions Competition for Our Healthcare Information Services and Technology Solutions and Business Porex Competition in our 2002 Annual Report on Form 10-K.

*The performance of our businesses depends on attracting and retaining qualified executives and employees*

Our performance depends on attracting and retaining key personnel, including executives, product managers, software developers and other technical personnel and sales and marketing personnel. Failure to

**Table of Contents**

do so could have a material adverse effect on the performance of our business and the results of our operations.

*We may not be successful in protecting our intellectual property and proprietary rights*

Our intellectual property is important to all of our businesses. We rely on a combination of trade secret, patent and other intellectual property laws and confidentiality procedures and non-disclosure contractual provisions to protect our intellectual property. We believe that our non-patented proprietary technologies and business and manufacturing processes are protected under trade secret, contractual and other intellectual property rights. However, those rights do not afford the statutory exclusivity provided by patented processes. In addition, the steps that we take to protect our intellectual property, proprietary information and trade secrets may prove to be inadequate and, whether or not adequate, may be expensive.

There can be no assurance that we will be able to detect potential or actual misappropriation or infringement of our intellectual property, proprietary information or trade secrets. Even if we detect misappropriation or infringement by a third party, there can be no assurance that we will be able to enforce our rights at a reasonable cost, or at all. In addition, our rights to intellectual property, proprietary information and trade secrets may not prevent independent third-party development and commercialization of competing products or services.

*Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services*

We could be subject to claims that we are misappropriating or infringing intellectual property or other proprietary rights of others. These claims, even if not meritorious, could be expensive to defend and divert management's attention from our operations. If we become liable to third parties for infringing these rights, we could be required to pay a substantial damage award and to develop non-infringing technology, obtain a license or cease selling the products or services that use or contain the infringing intellectual property. We may be unable to develop non-infringing products or services or obtain a license on commercially reasonable terms, or at all. We may also be required to indemnify our customers if they become subject to third party claims relating to intellectual property that we license or otherwise provide to them, which could be costly.

*We have incurred and may continue to incur losses*

We began operations in January 1996 and have incurred net losses from operations in each year since our inception and, as of March 31, 2003, we had an accumulated deficit of \$10.2 billion. Although we generated net income, determined in accordance with generally accepted accounting principles, in the quarter ended September 30, 2002, we incurred a net loss for the year ended December 31, 2002 and the quarter ended March 31, 2003. We currently intend to continue to invest in infrastructure development, applications development, sales and marketing, and acquisitions and whether we continue to incur losses in a particular period will depend on, among other things, the amount of such investments and whether those investments lead to increased revenues.

*We may be subject to litigation*

Our business and operations may subject us to claims, litigation and other proceedings brought by private parties and governmental authorities. For information regarding certain proceedings to which we are currently a party, see "Legal Proceedings" in our 2002 Annual Report on Form 10-K.

*Business combinations and other transactions may be difficult to complete and, if completed, may have negative consequences for our business and our security holders*

We intend to seek to acquire or to engage in business combinations with companies engaged in complementary businesses. In addition, we may enter into joint ventures, strategic alliances or similar arrangements with third parties. These transactions may result in changes in the nature and scope of our



**Table of Contents**

operations and changes in our financial condition. Our success in completing these types of transactions will depend on, among other things, our ability to locate suitable candidates and negotiate mutually acceptable terms with them, as well as the availability of financing. Significant competition for these opportunities exists, which may increase the cost of and decrease the opportunities for these types of transactions. Financing for these transactions may come from several sources, including:

cash and cash equivalents on hand and marketable securities,

proceeds from the incurrence of indebtedness, and

proceeds from the issuance of additional common stock, preferred stock, convertible debt or other securities.

Our issuance of additional securities could:

cause substantial dilution of the percentage ownership of our stockholders at the time of the issuance,

cause substantial dilution of our earnings per share, and

adversely affect the prevailing market price for our outstanding securities.

We do not intend to seek security holder approval for any such acquisition or security issuance unless required by applicable law or regulation or the terms of existing securities.

*Our business will suffer if we fail to successfully integrate acquired businesses and technologies or to assess the risks in particular transactions*

We have in the past acquired, and may in the future acquire, businesses, technologies, services, product lines and other assets. The successful integration of the acquired businesses and assets into our operations, on a cost-effective basis, can be critical to our future performance. The amount and timing of the expected benefits of any acquisition are subject to significant risks and uncertainties. These risks and uncertainties include, but are not limited to, those relating to:

our ability to maintain relationships with the customers of the acquired business;

our ability to cross-sell products and services to customers with which we have established relationships and those with which the acquired business has established relationships;

our ability to retain or replace key personnel;

potential conflicts in payer, provider, strategic partner, sponsor or advertising relationships;

our ability to coordinate organizations that are geographically diverse and may have different business cultures; and

compliance with regulatory requirements.

We cannot guarantee that any acquired businesses will be successfully integrated with our operations in a timely or cost-effective manner, or at all. Failure to successfully integrate acquired businesses or to achieve anticipated operating synergies, revenue enhancements or cost savings could have a material adverse effect on our business, financial condition and results of operations.

Although our management attempts to evaluate the risks inherent in each transaction and to value acquisition candidates appropriately, we cannot assure you that we will properly ascertain all such risks or that acquired businesses and assets will perform as we expect or enhance the value of our company as a whole. In addition, acquired companies or businesses may have larger than expected liabilities that are not covered by the indemnification, if any, we are able to obtain from the seller.

## **Table of Contents**

*We may not be able to raise additional funds when needed for our business or to exploit opportunities*

Our future liquidity and capital requirements will depend upon numerous factors, including the success of the integration of our businesses, our existing and new applications and service offerings, competing technologies and market developments, potential future acquisitions and additional repurchases of our common stock. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. There can be no assurance that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders.

### **ITEM 3. *Quantitative and Qualitative Disclosures About Market Risk***

#### **Interest Rate Sensitivity**

The primary objective of our investment activities is to preserve principal and maintain adequate liquidity, while at the same time maximizing the yield we receive from our investment portfolio. This objective is accomplished by adherence to our investment policy, which establishes the list of eligible securities and credit requirements for each investment.

Changes in prevailing interest rates will cause the principal amount of the investment to fluctuate. To minimize this risk, we maintain our portfolio of cash equivalents, short-term investments and marketable securities in commercial paper, non-government debt securities, money market funds and highly liquid United States Treasury notes. We view these high grade securities within our portfolio as having similar market risk characteristics.

Principal amounts expected to mature are \$9.1 million, \$200.2 million, \$23.0 million, \$141.1 million and \$52.0 million during the remainder of 2003, 2004, 2005, 2006 and 2007, respectively. These include investments totaling \$130.0 million in federal agency notes that are callable subjecting us to interest rate risk on the reinvestment of these securities. We believe that the impact of any call and resulting reinvestment of proceeds would not have a material effect on our financial condition or results of operations.

We have not utilized derivative financial instruments in our investment portfolio.

#### **Exchange Rate Sensitivity**

Currently, substantially all of our sales and expenses are denominated in United States dollars; however, Porex is exposed to fluctuations in foreign currency exchange rates, primarily the rate of exchange of the United States dollar against the Euro. This exposure arises primarily as a result of translating the results of Porex's foreign operations to the United States dollar at exchange rates that have fluctuated from the beginning of the accounting period. Porex has not engaged in foreign currency hedging activities to date. Foreign currency translation gains (losses) were \$.3 million and \$(.2) million, during the three month periods ended March 31, 2003 and 2002, respectively.

### **ITEM 4. *Controls and Procedures***

WebMD management, including the Chief Executive Officer and Chief Financial Officer, have conducted an evaluation of the effectiveness of WebMD's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based on that evaluation, which was completed during the 90 days prior to the date on which this Quarterly Report was filed with the Commission, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective in ensuring that all material information required to be filed in this Quarterly Report has been made known to them in a timely fashion. There have been no significant changes in internal controls, or in factors that could significantly affect internal controls, subsequent to the date the Chief Executive Officer and Chief Financial Officer completed their evaluation.

**Table of Contents**

**PART II**

**OTHER INFORMATION**

**ITEM 2. *Changes in Securities and Use of Proceeds***

On January 14, 2003, WebMD issued 28,269 shares of WebMD common stock to Luna I Investors, LLC in a transaction exempt from registration under Section 3(a)(9) of the Securities Act. The shares were issued upon exercise of an outstanding warrant.

On February 18, 2003, WebMD issued 594,988 shares of WebMD common stock to Misys Technology Investments, Ltd. in a transaction exempt from registration under Section 3(a)(9) of the Securities Act. The shares were issued upon exercise of an outstanding warrant.

On March 4, 2003, WebMD issued an aggregate of 88,946 shares of WebMD common stock to three individuals in transactions exempt from registration under Section 3(a)(9) of the Securities Act. The shares were issued upon exercise of outstanding warrants originally issued to Gleacher & Co. and transferred by it to the individuals.

**ITEM 6. *Exhibits and Reports on Form 8-K***

(a) The exhibits listed in the accompanying Exhibit Index on page E-1 are filed as part of this Quarterly Report, other than Exhibits 99.1 and 99.2, which are being furnished to accompany this Quarterly Report solely for the purpose of complying with Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and shall not be deemed filed as part of this Quarterly Report.

(b) The following Current Reports on Form 8-K were filed during the quarter ended March 31, 2003:

Current Report on Form 8-K, filed February 19, 2003, regarding the date of announcement of results for the quarter and year ended December 31, 2002 and termination of the divestiture process for Porex.

Current Report on Form 8-K, filed March 14, 2003, regarding announcement of WebMD's results for the quarter and year ended December 31, 2002.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEBMD CORPORATION

By: /s/ ANTHONY VUOLO

---

Anthony Vuolo  
*Executive Vice President and Chief  
Financial Officer*

Date: May 13, 2003

**Table of Contents**

**CERTIFICATIONS PURSUANT TO**

**SECTION 302 OF THE  
SARBANES-OXLEY ACT OF 2002**

I, Roger C. Holstein, certify that:

1. I have reviewed this quarterly report on Form 10-Q of WebMD Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
  - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
  - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: May 13, 2003

/s/ ROGER C. HOLSTEIN

---

Roger C. Holstein  
Chief Executive Officer  
(Principal executive officer)

**Table of Contents**

I, Anthony Vuolo, certify that:

1. I have reviewed this quarterly report on Form 10-Q of WebMD Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
  - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
  - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and
  - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: May 13, 2003

/s/ ANTHONY VUOLO

---

Anthony Vuolo  
*Executive Vice President and Chief  
Financial Officer  
(Principal financial officer)*

**Table of Contents**

**EXHIBIT INDEX**

| Exhibit No. | Description  |
|-------------|--|
| 3.1         | Tenth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to Registrant's Report on Form 8-K filed September 13, 2000), as amended by Certificate of Change of Registered Agent and Location of Registered Office (incorporated by reference to Exhibit 3.1 to Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2001) |
| 3.2         | Amended and Restated Bylaws of Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 to Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2001)   |
| 99.1        | Statement of Chief Executive Officer of Registrant Pursuant to 18 U.S.C. § 1350  |
| 99.2        | Statement of Chief Financial Officer of Registrant Pursuant to 18 U.S.C. § 1350  |